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ABSTRACT
Epilepsy is a common neurological disease characterized by recurrent, usually unprovoked seizures due to
excessive discharge of cerebral neurons. Medical therapy is the standard treatment for the majority of epilepsy
patients. New antiepileptic drugs (AED), vigabatrin (VGB) and tiagabine (TGB) among others, have entered the
market in recent years as a result of rational drug development. VGB and TGB increase the amount of inhibitory
neurotransmitter, gamma-amino butyric acid (GABA), in the central nervous system, with different specific
mechanisms of action. VGB is a selective irreversible inhibitor of GABA-transaminase and TGB blocks the
neuronal and glial reuptake of GABA. They are approved for the adjunctive management of partial epilepsy, and
in addition VGB is approved for initial monotherapy in the management of infantile spasms, and for seizures
caused by tuberosis sclerosis. Since 1997, reports of severe concentric visual field defects in association with the
use of VGB have been published. The purpose of the present study was to determine the causality, prevalence,
risk factors and prognosis of visual field defects in patients treated with initial VGB monotherapy or with VGB
add-on therapy. The effect of TGB monotherapy on visual fields was examined in order to detect any possible
class effect of GABAergic AEDs. In addition, visual functions were assessed more comprehensively with
psychophysical tests in patients with VGB, TGB or carbamazepine (CBZ) monotherapy.
Kinetic visual fields were examined in 35 epilepsy patients (aged 20-74 years) on VGB monotherapy, in
25 patients (aged 17-62 years) on VGB add-on therapy, in 15 patients (aged 31-71 years) on TGB monotherapy,
in 18 patients (aged 20-70 years) on CBZ monotherapy, and in 18 healthy controls (aged  23-74 years). Color
vision and contrast sensitivity tests were performed in 32 epilepsy patients on VGB monotherapy, and in the
patients on TGB or CBZ monotherapy. The prognosis of VGB-associated visual field defects was evaluated in
a follow-up examination after 4 to 38 months in 55 patients, 29 of whom had discontinued VGB therapy. Visual
fields were graded as normal, mildly constricted or severely constricted according to their temporal extents. 
Bilateral concentric visual field constriction was found in 24 of 60 (40%) patients treated with VGB
therapy. The constriction was severe in 8 (13%) and mild in 16 (27%) patients. There was no difference between
monotherapy and add-on therapy groups. Statistical analysis showed that concentric constriction of the visual
fields was related to the use of VGB. The extents of the visual fields were significantly constricted in the VGB
monotherapy group as compared with the visual fields of patients in the CBZ monotherapy group or healthy
controls (p<0.01). Most patients were asymptomatic. Visual field defects were neither reversible after cessation
of the drug nor progressive with continued treatment. The patients on TGB monotherapy or on CBZ
monotherapy had no concentric visual field defects. Acquired color vision defects were found in  32% of VGB
monotherapy patients, in 50% of TGB monotherapy patients, and in 28% of CBZ monotherapy patients. Color
vision and contrast sensitivity were significantly impaired in patients who had VGB-associated visual field
defects. Contrast sensitivity was not affected by  TGB or CBZ.
The findings of the present study confirm the relationship between AED treatment with VGB and
concentric visual field defects, and the irreversible nature of these defects. Neither clear risk factors nor a class
effect of GABAergic AEDs was found. All the AEDs studied may cause impairment in visual function, but the
most significant changes were found in patients who  received long-term VGB treatment, supporting the idea of
the retinal toxicity of VGB. The exact mechanism of VGB-associated visual field defects is not clear and future
research should elucidate the pathophysiological mechanism of the toxicity of VGB. If VGB is used, regular
visual field examination should be performed before the start of treatment and at regular intervals during
treatment.
 
National Library of Medicine Classification: WW 105, QV 85
Medical Subject Headings: anticonvulsants/adverse effects; carbamazepine; color perception/drug effects;
contrast sensitivity/drug effects; epilepsies, partial/drug therapy; glare; perimetry; vigabatrin/adverse effects;
visual fields/drug effects
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1  INTRODUCTION
Epilepsy is a common neurological disease characterized by recurrent, usually unprovoked seizures
due to excessive discharge of cerebral neurons. Around 10% of the population will experience a
seizure at some time and about 1% of the population has epilepsy (Keränen et al., 1997). The
majority of epilepsy patients needs long-term antiepileptic drug (AED) therapy in some phases of
their life. A number of new AEDs have entered the market in recent years as a result of  rational drug
development. Potentiating the action of the main inhibitory neurotransmitter gamma-amino butyric
acid (GABA) is one of the mechanisms of action of these drugs (Macdonald and Kelly, 1994).
Vigabatrin (VGB) and tiagabine (TGB) are two drugs of the new generation of AEDs, both of which
exert their pharmacological effects via the GABAergic system. They both are approved for the
adjunctive management of partial epilepsy, and in addition, VGB is approved for the initial
management of infantile spasms.
Until the appearance of the first reports about visual field defects associated with VGB therapy
(Eke et al., 1997), VGB had a reputation for good efficacy and excellent tolerability (Marson et al.,
1997). During the clinical development, only rare cases (less than 1:1000) of symptomatic visual field
constrictions and retinal disorders were reported in association with VGB treatment. Between 1997
and 1998, symptomatic and asymptomatic concentric visual field constrictions and
electrophysiological changes suggestive of retinal toxicity were reported in several case reports
mostly of drug-resistant epilepsy patients receiving VGB concurrently with other AEDs (Krämer et
al., 1997, Wilson and Brodie, 1997, Wong et al., 1997, Krauss et al., 1998, Leach et al., 1998,
MacKenzie and Klistoner, 1998, Ruether et al., 1998). The prevalence rates for VGB-associated
visual field defects varied from about 30% to 50% (Daneshvar et al., 1999, Lawden et al., 1999, Wild
et al., 1999, Hardus et al., 2000a). 
The exact mechanism of visual field defects associated with the use of VGB  is not known, and
on the basis of their GABAergic mechanism of action, the question  has been raised whether TGB
and other GABAergic AEDs cause visual field loss in a similar manner to that of VGB (Beran et al.,
1998, 1999).
In the present study, the causal relationship between concentric visual field defects and VGB
treatment, and the prevalence and prognosis of visual field defects were assessed in epilepsy patients
treated with  initial long-term VGB monotherapy, thus avoiding the confounding effect of AED
polypharmacy. Another aim of the study was to evaluate the effect of VGB, TGB and carbamazepine
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(CBZ) on visual function as many established and new AEDs have been found to affect color vision,
contrast sensitivity and glare sensitivity (Bayer, 1991, Bayer et al., 1995a,b, 1997, Steinhoff et al.,
1997a,b).
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2 REVIEW OF THE LITERATURE
2.1 Anatomy and physiology of the retina
2.1.1 Overview
The principal function of the retina is to transduce the light from the outside world into neural signals,
and to process and transmit these signals in a language usable by the brain. The outer part of the
retina comprises a single layer of retinal pigment epithelium (RPE) cells which supply the metabolic
needs of the neural retina. The neurosensory retina consists of neural, glial and vascular elements.
In the light microscopy, the neural retina may be subdivided into nine horizontal layers (Figure
1). It is composed of three layers of nerve cell bodies and two layers of synapses. The outer nuclear
layer (ONL) contains cell bodies of the rods and cones, the inner nuclear layer (INL) contains cell
bodies of  bipolar, horizontal and amacrine cells, and the ganglion cell layer (GCL) contains cell
bodies of ganglion cells and displaced amacrine cells. These nerve cell layers are divided by two
plexiform layers which contain the functional synapses. In the outer plexiform layer (OPL), there are
connections between photoreceptors and vertically running bipolar cells and horizontally oriented
horizontal cells. The inner plexiform layer (IPL) connects bipolar cells and amacrine cells to ganglion
cells. The non-myelinated axons of ganglion cells comprise the nerve fiber layer of the retina  (Kolb,
1991a). 
Figure 1. The layers and cells of the retina.
20
The second order neurons, bipolar cells, connect photoreceptors to the third order neurons,
ganglion cells. In human retina, nine different bipolar cell types are revealed by Golgi staining, eight
for cones and one for rods (Kolb, 1991a). The cone bipolar cells can synapse directly between
photoreceptors and ganglion cells while the rod bipolar cells synapse with various amacrine cell types
but not directly with ganglion cell dendrites. This allows both convergence and divergence of signals
before synaptic output to ganglion cells.
Three different horizontal cell types make neural connections from photoreceptors to
photoreceptors and to bipolar cells in the OPL. Horizontal cells send mainly inhibitory information
back to cones and rods, and forward to bipolar cells. They are thought to be involved with the spatial
and spectral center-surround antagonism of the retina, and thus to affect both contrast sensitivity and
color vision (Perlman and Normann, 1990, Kolb, 1991a,b).
Amacrine cells interact at the second synaptic level (IPL) modulating the visual signal from the
cones and rods to the ganglion cells. On the basis of their Golgi staining properties, intracellular
recordings, immunocytochemical staining and electron microscopic findings, at least 25 different
amacrine cell types have been identified in human retina (Kolb, 1991a). Most vertebrate amacrine
cells are found to be inhibitory and, like horizontal cells, they interact with the spectral and spatial
antagonism (Falk, 1991). Interplexiform cells are a subgroup of retinal cells which connect outer and
inner plexiform layers (Kolb, 1991a). 
Ganglion cells receive output from bipolar cells modulated by negative feedback from amacrine
cells.  Approximately 20 different ganglion cell types have been distinguished, but two of them are
the most dominating (Kolb, 1991a). The small cell system responds tonically and conducts slowly,
and mediates the visual acuity and color vision and projects to the parvocellular layers of the lateral
geniculate nucleus. The large cell system responds phasically and quickly and mediates peripheral
visual function and movement detection, and projects to the magnocellular layer of lateral geniculate
nucleus (Kolb, 1991a,b).
Three different glial cells can be identified in the human retina. The principal glial cells, Müller
cells, stretch  through the whole thickness of the neural retina and provide structural support and
nutrition for it. Müller cells protect neurons from exposure to excess neurotransmitters, using uptake
mechanisms to recycle neurotransmitters such as glutamate and GABA (Napper and Kalloniatis,
1995). The role of other glial cells, astrocytes and microglia is mostly architectural support of
vascular and neural tissues of the retina. Their possible metabolic properties have not yet been
established.
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 2.1.2 GABA and GABAergic cells in the retina
Retinal neurotransmitters produce either excitatory (glutamate and acethylcholine) or inhibitory
(GABA and glycine) effects by regional hyperpolarisation or depolarisation in the postsynaptic target
neuron. GABA is the major inhibitory neurotransmitter in the central nervous system (CNS) and
retina, and plays an important role in processing visual information. In rabbit retina, GABA has been
localized into the OPL, INL, IPL and GCL (Ehinger, 1970, Perez and Davanger, 1994, Crook and
Pow, 1997). In humans, GABA-immunoreactivity has been found in amacrine, bipolar and
interplexiform cells in the INL,  and in displaced amacrine cells in the GCL (Crooks and Kolb, 1992,
Van Haesendonck and Missotten, 1993). Approximately 40% of the amacrine cells in human retina
are found to be immunoreactive for GABA (Crooks and Kolb, 1992). The GABAergic feedback from
amacrine to bipolar cells probably control bipolar cell output to ganglion cells. 
GABA is synthesized in the presynaptic cell terminal from glutamate by the enzyme glutamic acid
decarboxylase (GAD) and metabolized to succinate by GABA-transaminase (GABA-T) and succinic
semi-aldehyde dehydrogenase in presynaptic neurons and glial cells (Figure 2). GABA inhibits
neuronal firing via the receptors present on the postsynaptic cell membrane by opening Cl  channels,-
resulting in a reduction of neuronal excitability. Three types of GABA receptors, GABA , GABAA  B
and GABA ,with numerous subunits, have been characterized on the basis of their pharmacologicalC  
and electrophysiological properties (Feigenspan and Bormann, 1998). Both GABA  and GABAA  C
receptors gate chloride-selective ion channels, but their pharmacological properties differ markedly.
GABA  receptors are highly enriched  in the mammalian retina, and they are found exclusively in theC
axon terminals of  bipolar cells in IPL, where they coexist with the GABA  receptors (Enz et al.,A
1996, Feigenspan and Bormann, 1998, Euler and Wässle, 1998). GABA  receptors  are enrichedC
more in rod than in cone bipolar axon terminals. They are 10 times more sensitive than GABAA
receptors (Enz et al.1996), and are responsible for small but sustained responses, while GABAA
receptors response rapidly and more powerful to brief stimulation (Feigenspan and Bormann, 1998,
Euler and Wässle, 1998). GABA  receptors have been identified in rodents in amacrine, bipolar,A
horizontal and ganglion cells (Hu et al., 1998, Feigenspan and Bormann, 1998, Euler and Wässle,
1998). GABA  receptors interact via gating K  and Ca  channels and have been shown to affectB
+  2+
visual signal processing in amphibians (Slaughter and Tian, 1993, Arnarsson and Eysteinsson, 1997)
and in rabbits (Zucker and Paryani, 1998), but  the role of GABA  receptors in the human retina hasB
not yet been resolved. 
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The activity of GABA is terminated by uptake into nerve cell terminals and glial cells by specific,
high-affinity transporters (GAT). In rodent retina, three of these transporters, GAT1, GAT2, and
GAT3 have been demonstrated in nerve cell processes in the IPL and in amacrine and Müller cells in
INL (Ruiz et al., 1994, Hu et al., 1999).
Figure 2. A diagram of a GABAergic synapse and the sites of action of vigabatrin and
tiagabine (Leach and Brodie, 1998). (GABA = gamma-amino butyric acid, GABA-T = GABA-
transaminase, GAD = glutamic acid decarboxylase, GAT = GABA-transporter).
2.2 Visual function tests
2.2.1 Overview
Visual function tests are used to gain information from several levels of the above described neuronal
network and visual signal transduction in vivo (Table 1). However, the final establishment of the
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visual perception takes place in the visual cortex after a modulation in the lateral geniculate nucleus.
The following section deals with those tests which are used in the present series of studies.
Table 1. Visual function tests.
Test Measuring the principal function of
Visual acuity Foveal cone photoreceptors
Visual field Photoreceptors, retinal network and visual pathways
Color vision Foveal cone photoreceptors (photopigments) and retinal
network 
Contrast sensitivity Photoreceptors and retinal network
Glare sensitivity Photoreceptors
Dark adaptation Photoreceptors and retinal network
Visual evoked potentials (VEP) Visual pathways
Electroretinogram (ERG)
a-wave Photoreceptors 
b-wave Müller and bipolar cells
 Oscillatory potentials Amacrine cells
Electro-oculogram (EOG) Photoreceptors and retinal pigment epithelium
2.2.2 Visual fields
Visual field examination is essential in the diagnosis of many ophthalmic and neurological disorders.
The normal visual field extends about 100o temporally, 60o nasally, 60o superiorly and 75o inferiorly
(Anderson, 1987). The contours of the visual field can be surveyed in two ways, by kinetic and by
static perimetry.
In the kinetic perimetry, the boundaries of the visual field are measured by the operator with
moving stimulus with different light intensity and spot size, and it is ideally suited for examination of
the peripheral visual field. Peripheral retina is specialized for the detection of moving stimuli which
is a benefit in this method.
The reliability of the kinetic perimetry depends on the examiner’s skills. He or she continuously
interacts with the patient and assess the reliability of the testing. This is a benefit in children and
patients with slow reaction time, as the examiner can change the speed with which the stimulus is
moved. However, this is not always advantageous as the speed of the stimulus may also influence the
extent of the measured field. Fixation losses are not documented quantitatively but unreliable or
contradictory answers can quickly be checked again by catch trials. The reliability of kinetic perimetry
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has also been criticized on the grounds that the operator might consciously or unconsciously attempt
to obtain a “correct” field which may cause a bias in the results. However, in a comparison between
kinetic and automated static perimetries in normal controls, glaucoma patients and neurologic
patients, Beck et al. (1985) found that only 2% of Goldmann visual field tests were unreliable,
whereas 9% of the Humphrey results were inadequate, although both instruments were found to be
sensitive and accurate in detecting visual field defects.
In computerized static perimetry, thresholds of 75-80 points arrayed in a regular grid pattern
within 30o radius of the visual field are determined. The full threshold strategy determines the precise
height and shape of the hill of vision, and it has been found to be efficient in detecting a decrease in
visual sensitivity in the central retina, for instance in glaucoma patients, but it has also been used
successfully in the diagnosis of neuro-ophthalmic diseases (Schindler and McCrary, 1981, Keltner and
Johnson, 1983, Beck et al., 1985). Due to the limited spatial extent, however, the examination of the
central 30o radius of the visual field may not reveal mild to moderate visual field losses in the
periphery. The full threshold strategy for the visual field within 60o radius is particularly time
consuming and demanding for the subject. In the suprathreshold or screening strategies, the stimulus
is presented 6 dB brighter than the expected age-dependent threshold of each point (Humphrey Field
Analyser II, HFA II, User´s Guide, 1998). According to this strategy, larger areas, i.e.120 points
within 60o radius of visual field can be quickly examined, but the screening strategy does not quantify
threshold sensitivities.
Standardized stimulus characteristics, reliability criteria and statistical programs of automated
perimetries help the detection of change in repeated visual field examinations. However,
interpretation of the computerized static perimetry results may be adversely influenced by the
physiological variability of the patient response during (short term fluctuation) or between (long term
fluctuation) the examinations. A learning effect as well as a fatigue effect influence to the outcome of
automated perimetry (Beck et al., 1985, Wild et al., 1991, Olsson et al., 1997). 
Independent of the testing method used, the outcome of visual field tests must always be
interpreted in the context of many patient-related factors. The visual acuity, age and cognitive
capacity of the patient are the most important factors for obtaining reliable results in visual field
examination (Egge, 1984). Generally, reliable assessment of visual fields in children over 9 years of
developmental age is possible with perimetry (Appleton, 1998), especially with kinetic perimetry, but
in a recent study by Morales and Brown (2001), short automated perimetry was found to be feasible
in children over 7 year old. Reliable assessment of visual fields in young children and in people with
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learning difficulties or poor concentration is seldom possible since  all types of visual field tests
require sustained concentration by the patient.
2.2.3 Contrast sensitivity
The measuring of contrast sensitivity, i.e. the minimal contrast required to detect the intensity
difference between the luminance of the object and that of its surroundings, allows a more functional
assessment of visual system than using a conventional visual acuity chart. For grating patterns,
contrast is defined as the difference of maximal and minimal luminance divided by the sum of them
(Michelson contrast). For letter contrast sensitivity charts, contrast is defined as the difference in
luminance between the letter and its background, divided by the luminance of the background (Weber
contrast). This value ranges from 0 to 1 and is usually multiplied by 100 to get a percentage contrast.
The lowest detectable contrast is called the contrast threshold of the subject. The contrast sensitivity
is defined as the reciprocal of the contrast threshold, i.e. 1/ contrast, ranging from 1 to infinity
(Wolfe, 1990).
Contrast sensitivity tests measure the minimal contrast required to detect different spatial
frequencies. The spatial frequency of a grating is the number of cycles (one black and one white bar)
per degree of visual angle (cpd). The peak sensitivity is about 5 cpd and it falls off at higher and
lower spatial frequencies. In clinical tests, contrast sensitivity value for either one (for instance, Pelli-
Robson 1 or 3 cpd) or several (for instance, Vistech 1.5 to 18 cpd) spatial frequencies can be
examined.
2.2.4 Glare sensitivity
The physiologic basis for glare sensitivity is the bleaching of the visual pigments in intense light  and
the resynthesis of the photosensitive pigments after the exposure of light. The macular photostress
test is used in the differential diagnosis of macular diseases and optic neuropathies in patients with
decreased visual acuity. Patients with macular disturbances have a prolonged recovery time from
glare instead of the normal recovery time found in patients with optic neuropathies (Glaser et al.,
1977). The effect of glare on visual perception can be measured with the brightness acuity test
(BAT), either in high contrast (visual acuity) or low contrast (contrast sensitivity) conditions (Prager,
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1990). Impaired brightness acuity is commonly found in anterior eye diseases, such as cataract or
corneal opacity.
2.2.5 Color vision
Many diseases in the retina and visual pathways, as well as toxic agents and drugs, can cause
deterioration in color vision. Chromatic mechanisms are highly susceptible to incipient injuries, so
that acquired color vision defects may be the first sign of ocular toxicity. Short wavelength  cones are
particularly vulnerable to acquired damage resulting in a blue (tritan) defect, but also red (protan) or
green (deutan) defects can occur as a consequence of toxic injury (Hart, 1987).
Clinical color vision examination can be carried out in two stages. Plate tests such as Ishihara
(1957),  AO-HRR (Hardy et al., 1957) and Standard Pseudoisochromatic Plates Part 2 (SPP2,
Ichikawa et al., 1983) answer only the question whether the patient has normal color vision or not,
and only give a hint for the exact diagnosis. In the second stage, the definite diagnosis and the
assessment of the severity of the defect can be done with the arrangement tests, for instance,
Farnsworth-Munsell 100 Hue test (FM100, Farnsworth, 1957). The colored caps have to be arranged
according to the hues. The score of each cap is calculated as the sum of the absolute differences
between the adjacent caps. The total errors are usually converted as square roots and divided into
blue-yellow and red-green partial scores (Kinnear, 1970). To calculate an axis, the square root of the
red-green errors is subtracted from the square root of blue-yellow errors (Smith et al., 1985). The
subject has a color vision defect if  the error score is above the age-related upper limit (Verriest et al.,
1982, Mäntyjärvi 2001) and/or if an axis (red, green or blue) can be found in the result diagram
(Smith et al., 1985).
Using an anomaloscope we can examine the ability of the subject to equate a mixture of two
monochromatic colors with a third comparison wavelength (Birch et al., 1979). In the Rayleigh
equation, green (545 nm) and red (670 nm) primaries are mixed, and the mixture is compared to
match with yellow (590 nm). In the Moreland equation, blue (436 nm) and green (490 nm) primaries
are mixed, and the mixture is compared with cyan blue (480 nm + 580 nm). The scale of the
instrument is divided into 100 units, 0 representing the green color and 100 the red color in the
Rayleigh equation, and 0 in the scale representing the blue color and 100 the green color in the
Moreland equation. The proportion of mixed primaries used to obtain a match is given as mid
matching point (MMP), and the range of mixtures which will be accepted as matching the reference
color is given as the matching range (MR) (Birch et al., 1979). Subjects with color vision defects do
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not accept the normal MMP requiring an excess of red, green or blue color. This deviation from
normality is expressed mathematically by the anomalous quotient (AQ). The AQs of normal
trichromats fall between about 0.7 and 1.4 (Birch et al., 1979, Roth, 1984, Maaranen et al., 2000).
The normal limits of MR vary from about 0 to 11 scale units (Roth, 1984, Maaranen et al., 2000).
2.3 Epilepsy and antiepileptic therapy with vigabatrin, tiagabine and carbamazepine
2.3.1 Epilepsy
Epilepsies are a group of symptom complexes arising from disordered brain functions that themselves
may be secondary to a variety of pathologic processes, such as brain injuries, infections, neoplasms
and vascular diseases. The common and fundamental characteristic of epilepsies are recurrent, usually
unprovoked epileptic seizures. These, in turn, are a consequence of a sudden, excessive,
synchronous, abnormal firing pattern of neurons in a part of the brain, predominantly in the cerebral
cortex,  producing alterations in consciousness, behavior, emotion, motor function or sensation as
clinical manifestations (Engel and Pedley, 1997).
According to the Commission on Classification and Terminology of the International League
Against Epilepsy (ILAE, 1989), the disorder of the brain may be apparently localized and known as
“localization related” (partial), or generalized. Both localization related and generalized epilepsies and
syndromes are divided according to the etiology into idiopathic and symptomatic varieties. Idiopathic
epilepsies are not associated with brain lesions, neurological abnormalities other than seizures, or
cognitive impairment. The onset of manifestations are typically age-related. Conversely, in remote
symptomatic epilepsy, seizures are the consequence of a focal brain abnormality or other specific
etiology. When epilepsies are probably remote symptomatic, but of unknown etiology, they are
termed cryptogenic (Commission on Classification and Terminology of the ILAE, 1989).
Medical therapy is the standard treatment for the majority of epilepsy patients. The goal of the
therapy is the cessation of seizures with as few adverse effects as possible. The therapy is long-term,
even life-long, regular treatment with single (monotherapy) or several (add-on or polytherapy) drugs.
Therapy is tailored according to the type of epilepsy  (partial or generalized) (Kälviäinen et al., 1993,
Keränen et al., 1997). There are no clear differences in efficacy between first line monotherapy AEDs
for partial epilepsy such as carbamazepine (CBZ), phenytoin (DPH), valproate (VPA), lamotrigine
and oxcarbazepine (Mattson et al., 1985, Mattson et al., 1992, Brodie et al., 1995, Bill et al., 1997),
nor have the newer AEDs (gabapentin, levetiracetam, tiagabine (TGB), topiramate, vigabatrin (VGB)
and zonisamide) shown significant difference in efficacy or tolerability in a meta-analysis of trials in
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drug-resistant partial epilepsy (Chadwick et al., 1996, Marson and Chadwick, 2001). Therefore, the
choice of an AED in the treatment of an individual patient is a compromise between efficacy and
adverse effects. The withdrawal of AED therapy can be discussed with a patient suffering from partial
epilepsy after the patient has been seizure free for 2 to 5 years (Keränen et al., 1997).
The AEDs available today can be divided into three categories in terms of their mechanisms
of action (Macdonald and Kelly, 1994). Most commonly, the drugs affect the flow of sodium into the
cell via voltage-gated sodium ion channels. A sodium ion channel is a structure in the cell membrane
that is selectively permeable to sodium ions and is opened by changes in voltage across the cell
membrane. Secondly, AEDs may affect calcium flow via voltage gated calcium ion channels. The
third category of AEDs affect neurotransmitter receptors or neurotransmitter metabolism. The most
widely used first-line standard AEDs for partial epilepsy have been DPH and CBZ, which share
similar mechanisms of action, i.e., a voltage- and use-dependent block of voltage-sensitive sodium
channels. Among the new drugs, VGB and TGB are unique in that they were derived from
mechanistic-based drug discovery programs designed to identify effective AEDs that inhibit the
metabolism and the uptake of the inhibitory neurotransmitter GABA, respectively.
2.3.2 Vigabatrin
Vigabatrin, gamma-vinyl-GABA, was synthesized in the 1970s and was used clinically for the first
time in 1979. VGB is a structural analogue of GABA. It acts as a selective irreversible inhibitor of
GABA-T, the metabolizing enzyme of the re-uptaken GABA in the neurons and glial cells (Figure 2).
VGB increases GABA concentrations in the CNS of animals and humans and induces a dose-related
increase in free and total GABA in the cerebrospinal fluid (CSF) (Schechter et al., 1977, Neal and
Shah, 1990, Kälviäinen, 1992, Petroff et al., 1999). The anticonvulsant efficacy of VGB has been
shown in animals and humans (Schechter et al., 1977, Kälviäinen et al., 1995, Marson et al., 1997,
Cramer et al., 1999). The absorption of VGB from the gastrointestinal tract is rapid and almost
complete. It is not protein-bound or metabolized, and it is excreted via the kidneys. The peak serum
levels are attained within about 2 h and half-time of VGB is from 5 to 8h. VGB has been shown to be
well tolerated in long-term use, the most frequently reported adverse effects being fatigue, headache,
weight gain, depression, abnormal thinking and dizziness (Kälviäinen et al., 1995, Chadwick, 1999,
Ylinen et al., 1999, Guberman et al., 2000). Diplopia and nystagmus are the reported ophthalmic
adverse events in clinical trials (Cramer et al., 1999, Guberman et al., 2000). Despite rapid systemic
elimination, the effect of VGB in the CNS is long-term both in animals and humans (Arteaga et al.,
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1992, Valdizán et al., 1999). Screening of the plasma levels of VGB or other blood tests for safety
reasons is not recommended during treatment (Commission on antiepileptic drugs of the ILAE, 1993,
Tomson and Johannessen, 2000), although it has been shown that the levels of hepatic transaminases
are markedly lowered during VGB therapy (Van Parys et al., 1995, Guberman et al., 2000). VGB is
currently approved in over 65 countries world-wide for the adjunctive management of partial
epilepsy, which is not satisfactorily controlled by conventional therapy, for initial monotherapy in the
management of infantile spasms (West syndrome), and for seizures caused by tuberosis sclerosis.
2.3.3 Tiagabine
Tiagabine, nipecotic acid hydrochloride, has a unique mode of action involving GABA. It is a potent,
selective and specific inhibitor of both neuronal and glial presynaptic GABA uptake (Suszdak and
Jansen, 1995) (Figure 2). It binds to a single class of high-affinity binding sites, probably the GABA
transporter GAT-1 (Borden et al., 1994). Consequently, treatment with TGB leads to an increased
synaptic content of GABA and to enhancement of GABAergic transmission in the brain, resulting in
a cessation of seizures (Fink-Jensen et al., 1992, Morimoto et al., 1997, Dalby, 2000). TGB is rapidly
absorbed from the gastrointestinal tract  with peak concentrations seen within 30-90 minutes of
dosing. Protein  binding is high (96%), but because therapeutic plasma concentrations are in the
nanomolar range TGB does not displace highly protein-bound drugs. TGB is widely metabolized in
humans, mainly by  the cytochrome P-450 enzyme CYP3A, less than 1% is excreted unchanged in the
urine, and no active metabolites have been identified (Leach and Brodie, 1998). The efficacy and
safety of TGB in the treatment of partial epilepsy have been shown in several studies (Kälviäinen et
al., 1998, Leppik et al., 1999, Loiseau, 1999, Fakhoury et al., 2000a). The antiepileptic and adverse
effects of TGB are more strongly related to the dose than to the plasma concentration, and there are
no specific guidelines for routine monitoring of laboratory values or concentrations of TGB (Tomson
and Johannessen, 2000). The most frequently reported adverse effects, such as dizziness, asthenia,
nervousness and tremor, are related to the CNS (Kälviäinen et al., 1998, Leppik et al., 1999). In
clinical trials of 494 patients treated with TGB, no ophthalmic adverse events were reported (Cramer
et al., 1999). TGB is registered in over 20 countries for the adjunctive treatment of adults and
children over 12 years with partial seizures with or without secondary generalization.
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2.3.4 Carbamazepine
Carbamazepine (CBZ) is a derivative of iminostilbene and is chemically related to tricyclic
antidepressants. It is an established first-line AED in the management of partial seizures with or
without generalization (Mattson et al., 1985, 1992, Keränen et al., 1997). Its principal mechanism of
action is to inhibit high-frequency neuronal firing of action potentials by blocking the voltage-gated
sodium channel (Macdonald and Kelly, 1994). The most common adverse effects of CBZ are fatigue,
diplopia, headache, dizziness, nausea, nystagmus and idiosyncratic skin reactions (Mattson, 1998,
Cramer et al., 1999). Screening the plasma levels of CBZ is routine in monitoring the therapeutic
response and neurotoxic effects of the drug (Commission on antiepileptic drugs of the ILAE, 1993).
The suggested reference values for CBZ range from 20 to 50 µmol/l. However, these ranges can be
ignored if the patient is seizure-free and untroubled by symptoms of toxicity.
2.4. The influence of vigabatrin on the visual system 
2.4.1 Retina and visual pathways
The preclinical toxicity studies of VGB showed changes in the retinas of albino (Sprague-Dawley)
rats, but not of pigmented (Lister-Hooded) rats (Butler et al., 1987). The changes in electron
microscope studies consisted of a disorganization of the ONL with displacement of the nuclei into the
rod layer affecting most the periphery of the retina. No other retinal layers or optic nerve were
affected. Histologically similar retinopathy was found earlier in albino rats during excessive exposure
to light, and it was suggested that the changes were caused by the toxicity of the light in albino rats.
In ophthalmoscopy or microscopic examination of the retinas after VGB exposure, no drug-
associated retinopathy has been observed in dogs or monkeys (Gibson et al., 1990).
The effects of VGB on retinal GABA have been studied in animal experiments with
immunocytochemical methods (Neal et al., 1989). GABA-immunoreactivity was observed in the
amacrine cell bodies, glial Müller cells and IPL of VGB treated animals. The authors suggested that
the administration of  VGB might cause the accumulation of GABA in retinal cells that do not
normally possess enough endogenous GABA to be detected by immunochemistry.  After
subcutaneous injection of VGB 50mg/kg and 100mg/kg, retinal GABA levels increased two fold to
levels significantly higher than those in control rats (p<0.0001) (Cubells et al., 1987). In two studies
by Neal et al. (1989 and 1990), acute intraperitoneal administration of VGB 250mg/kg to rats
reduced retinal GABA-T activity by 98% and increased the retinal GABA content 5-to-6-fold.
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Corresponding rates in the cerebral cortex were 80% and 2-fold, respectively. However, the increase
in GABA content in the retina was reduced by approximately 40% during chronic treatment of
250mg/kg VGB for 17 days (Neal and Shah, 1990). Active transport and accumulation of
immunolabelled VGB in the amacrine cells and Müller cells in the retina of rabbits, cats and monkeys
have been detected with both light and electron microscopes (Pow et al., 1996, Crook and Pow,
1997). Neither horizontal nor ganglion cells accumulate VGB in any species. It has been suggested
that long-term  GABA-T inhibition with VGB may cause an accumulation of GABA in the Müller
cells at a rate that may exceed the rate of catabolism by these cells (Neal et al., 1989).
Recently, it has been shown in rats that VGB treatment is associated with dose-related
decreases in the activity of GABA-T, and a consecutive rise in GABA levels in various brain regions,
but this effect was found to be more pronounced in retina (Sills et al., 2001). In addition, it was found
that VGB concentrations, although dose-related, were significantly higher in the retina than in the
other tissues investigated (Sills et al., 2001). 
The first concern about the toxic effects of VGB on the visual pathways arose during the
development of VGB, when drug-induced local microvacuolation of the white matter, or
intramyelinic edema, was found in animals (Butler et al., 1987, Butler, 1989). The dose-related
reversible microvacuolation occured at the hippocampus, cerebellum, reticular formation, optic tracts
and the columns of the fornix in rats and dogs, but not in monkeys (Gibson et al., 1990).
Histologically, the vacuolation was caused by myelin separation, and there was no evidence of
demyelination or damage in the neuronal cell bodies or nerve fibers. In addition to microvacuolation,
reactive astrocytosis and microglial activation were observed. The retina, optic nerve, spinal cord and
peripheral nerves were spared intact. Microvacuols in the white matter were reversible in all species
after cessation of VGB. 
In humans, no microvacuolation or other drug-associated pathology have been found in
neuropathologic examinations in patients with long-term VGB treatment (Butler 1989, Cannon et al.,
1991a,b, Sivenius et al., 1993, Cohen et al., 2000).
The only report of histopathological changes in the anterior visual pathways in an epilepsy
patient with a documented VGB-associated visual field defect has been recently reported by
Ravindran et al. (2001). The patient died from cardio-pulmonal arrest after visual field defects were
detected and documented. Histology of the retina showed severe atrophy of the peripheral retina and
less severe involvement of the macula. There was loss of ganglion cells and partial loss of nuclei from
the INL and ONL. The optic nerves and tracts showed severe atrophy mainly in the peripheral retinal
fibers but no microvacuolation was observed. 
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Individual case reports of patients with optic neuropathy have been reported during the
therapeutic use of VGB (Dieterle et al., 1994, Crofts et al., 1997, Buncic et. al., 2001). In these
patients, visual acuity as well as VEP latencies and amplitudes were decreased, indicating that the
optic nerve had been affected. Systemic cortisone therapy had favorable effects, but optic nerve
atrophy and concentric constriction of visual fields were observed later.
2.4.2 Visual fields
The diminishing size of the hill of vision, or concentric constriction of the visual field is a common
finding in many tapetoretinal dystrophies (Carr and Heckenlively, 1996). Furthermore, some toxic
agents and drugs, for instance chloroquine and quinine, may affect the retina or optic nerve,
producing concentric constriction of visual fields in addition to impaired visual acuity and retinal
changes (Lowes, 1976, Brinton et al., 1980, Danias and Brodie, 2001). Reports of visual field
constrictions associated with epileptic seizures (Trojan 1967) or AED therapy other than VGB
(Zrenner and Nowicki, 1985, Lorenz and Kuck, 1988, Bayer, 1991, Elder, 1992, Schmidt et al.,
1999, Schmitz et al., 1999, Malmgren et al., 2001) have been published, infrequently. Visual field
defects noticed during these AED therapies are mostly considered to be  a consequence of
intoxication or over-dosage, and usually they are resolved by dose reduction (Zrenner and Nowicki,
1985, Lorenz and Kuck, 1988, Bayer, 1991, Elder, 1992). The problem in this context is that
epilepsy occurs in association with many underlying CNS abnormalities (Meldrum, 1990). In
symptomatic epilepsy, visual pathways and the occipital cortex may be affected, producing visual
field defects which usually correspond to anatomical changes visible in CT or MRI.
During the development of VGB, only rare cases (less than 1 per 1000 patients treated) of
symptomatic visual field constriction and retinal disorders have been reported to the manufacturer. In
the early 1990s, sporadic reports of bilateral concentric visual field constriction in association with
VGB therapy were published (Bayer, 1991, Faedda et al., 1993). In the academic thesis by Bayer
(1991), six of eight patients who received VGB as add-on therapy with DPH had concentrically
constricted visual fields when examined with Octopus automated perimetry. At that time, the
causative role of VGB was not suspected, as in this particular study six of eleven patients treated
with DPH monotherapy had similar defects in their visual fields; this led the author to conclude that
DPH intoxication was the probable cause of these findings.
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The potential seriousness of VGB-attributed visual field loss was exposed in 1997 after case
reports by Eke et al. (1997). They described three patients aged 22 to 46 years who had severe
persistent visual field constriction with subnormal ERGs and EOGs after treatment with VGB for 2
to 3 years. The debate this provoked also resulted in the presentation of additional cases with similar
visual field losses in epilepsy patients who received VGB (Blackwell et al., 1997, Harding, 1997,
Krämer et al., 1997, Wilson and Brodie, 1997, Wong et al., 1997, Beran et al., 1998, Krauss et al.,
1998, Leach et al., 1998, MacKenzie and Klistorner, 1998, Ruether et al., 1998, Bjelajac et al.,
1999). However, short-term VGB exposure as a single-dose of 3g (Tiel-Wilck et al., 1995) or for a
period of 10 days with an increasing dose of 1 to 2 g (Harding et al., 1999) did not affect kinetic or
static perimeter assessment of visual fields in healthy volunteers.
2.4.2.1 Characteristics of VGB-associated visual field defects
The VGB-associated visual field defect is unique and specific in nature. In kinetic perimetry, it is
typically a bilateral, absolute concentric constriction of the visual field, the severity of which varies
from mild to severe (Eke et al., 1997, Miller et al., 1999, Hardus et al., 2000a). In  automated
perimetry, within a 30o radius from fixation, it shows as a nasal loss extending in an annulus over the
horizontal midline, with a relative sparing of the temporal field (Lawden et al., 1999, Wild et al.,
1999, Manuchehri et al., 2000). In the most severe cases, the visual field defect is concentric also
with static perimetry. However, nasal preponderance was not found by Hardus et al. (2000a) with
static or kinetic perimetry in a series of 157 patients. Schiefer et al. (2000) examined 109 VGB
patients with static Octopus perimetry using three-zone suprathershold strategy where the entire 90o
field can be examined, and found that the majority of defects did not affect the central 30o of the
visual field even when relative losses were taken into account. Nasal preference was found only if
absolute defect was considered. This discrepancy in the features of VGB-associated visual field
defect is probably based on the methodological differences between visual field examinations.
The lack of valid age-related normal values for kinetic visual field tests has confounded the
definition of VGB-associated visual field defect in different studies. Generally, kinetic visual fields
extending over 70o temporally, 40o superiorly, 45o nasally and 50o inferiorly measured with the
Goldmann stimulus I/4 have been considered as normal (Galán, 1968, Egge, 1984, Wild et al., 1999).
In their evaluation of kinetic perimetries, Hardus et al. (2000a,b, 2001a) used standardized Esterman
grid scores where the total number of not-seen points was calculated. Esterman grid consists of 100
34
points, and the missing of one point represents a visual field loss of 1%. The disadvantage of the
Esterman method is that the dots are distributed unequally over the four quadrants and that the points
are missing in the far periphery (Hardus et al., 2001a). More recently, Hardus et al. (2001a)
developed a new method to calculate the concentric constriction of the visual fields by surface-
measuring method and compared the results with those of normal controls. In the studies by Miller
et al. (1999) and Johnson et al. (2000), the mean radius of the visual field extents based on the
Diabetic Retinopathy Study Protocol was used. In addition,  the area of the visual field has been
measured planimetrically (Schmitz et al., 1999).
In studies reporting automated perimetry results using 30o  threshold strategy, the mean
deviation from age-corrected normals has been the main outcome measure (Arndt et al., 1999a,
Daneshvar et al., 1999, Lawden et al., 1999, Miller et al., 1999, Wild et al., 1999, Paul et al., 2001).
There are no normative values for the threshold strategy of the periphery from 30o to 60o, and this
has limited its usefulness in evaluations of VGB-associated visual field defect (Daneshvar et al., 1999,
Lawden et al., 1999). In studies where automated screening tests are used, results of normal controls
(Midelfart et al., 2000) or epilepsy patients without VGB medication (Manuchehri et al., 2000) have
been used as a reference. In statistical analyzes of kinetic or static visual fields, both age-matched
normal controls (Daneshvar et al., 1999, Wild et al., 1999, Midelfart et al., 2000, Hardus et al.,
2001a) and epilepsy patients without VGB therapy (Miller et al., 1999, Manuchehri et al., 2000) have
been used as a reference.
In all types of  visual field examination, a large number of more or less well-controlled
variables interfere with the results, including patient compliance and/or possible fatigue as well as the
skills of the perimetrist. Pre-existent visual field defects associated with the epilepsy or with the
background brain pathology may cause false positive findings but, on the other hand, worsening of
the pre-existing defect can also be overlooked. Automated threshold perimetry has been suggested
for its superior standardization in screening epilepsy patients taking VGB, but it is too demanding for
some epilepsy patient, and sometimes less demanding kinetic or confrontation perimetry is the only
feasible visual field test that can be carried out.
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2.4.2.2 Symptoms
Although the majority of the patients with VGB-associated visual field defects have been
asymptomatic (MacKenzie and Klistoner, 1998, Rao et al., 1998, Daneshvar et al., 1999, Wild et al.,
1999, Hardus et al., 2000a and 2001a, Gross-Tsur et al., 2000, Iannetti et al., 2000), there have been
also symptomatic cases. Patients have complained about blurred vision, oscillopsia, tunnel vision and
difficulties in movement, for instance bumping into objects (Blackwell et al., 1997, Eke, 1997, Wilson
and Brodie, 1997, Wong et al., 1997, Krauss et al., 1998, Ruether et al., 1998, Arndt et al., 1999a,
Lawden et al., 1999, Manuchehri et al., 2000). In a minority of patients the defect was so severe that
it limited their ability to perform a variety of activities of daily living. Some of the patients had not
realized that their symptoms were of visual origin, but had thought that they were caused by
clumsiness or drowsiness. This increased the number of patients, who were initially asymptomatic and
only realized the cause of their  problems after formal visual field examination.
The difficulty in recognizing the symptoms has obviously also led to the exceptional delay in
observing this common adverse effect of VGB. For example, Wilton et al. (1999) have published an
observational cohort study based to a prescription event monitoring study covering the period from
1991 to 1994 with an extended follow-up from 1998 to 1999. They revealed an incidence risk of
possible or probable VGB-associated visual field constriction of 7.0 per 1000 patients (33 affected of
4741 patients). However, this evaluation was done via questionnaires sent to physicians, the main
question being whether any serious adverse events or changes in vision had been reported. As current
data clearly indicate that the VGB-associated visual field constriction is asymptomatic until gross
field loss has occurred, most probably the unrecognized symptoms caused serious underestimation of
the risk in that study.
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2.4.2.3 Prevalence of vigabatrin-associated visual field defects
Systematic evaluations have shown variable prevalence rates for visual field constriction, as no
consensus has yet been reached either on the best method of visual field testing or on the unified
criteria for the presence of concentric visual field defects. The Marketing Authorization Holders
provided 1999 data from a pooled cohort of 335 VGB recipients aged over 14 years, all evaluated by
the same expert (Committee for Proprietary Medicinal Products, CPMP-report/1357/99). Of these,
31% (95% confidence interval (CI) 26% to 36%) manifested a VGB-attributed visual field defect;
this compared with a 0% (upper 95% CI 3%) in an unexposed control cohort. The published data
relating to adult study populations by different investigators give a similar overall prevalence, with
330 of 836 patients diagnosed with VGB-associated defects (39%, 95% CI 36% to 42%) (Table 2).
Table 2. Prevalence of VGB-associated visual field defects in adults in published studies.
Study Overall prevalence  Male prevalence  Female prevalence
Arndt et al., 1999a 11/19 (58%) 8/10 ( 80%)  3/9 (33%)
Daneshvar et al., 1999 12/41 (29%) not stated not stated
Hardus et al., 2000a 20/118 (17%) 15/72 (21%) 5/85 (6%)  
Lawden et al., 1999 12/31 (39%) not stated not stated  
Malmgren et al., 2001 19/99 (19%) not stated not stated
Manuchehri et al., 2000 11/20 (55%) 8/12 (67%) 3/8 (38%)
Midelfart et al., 2000 15/18 (83%) 9/9 (100%) 6/9 (67%)
Miller et al., 1999 8/20 (40%) not stated not stated
Newman et al., 2000 119/142 (84%) not stated not stated
Rebolleda et al., 2000 5/10 (50%) not stated not stated
Schiefer et al., 2000 32/109 (29%) not stated not stated
Specchio et al., 2000 28/41 (68%) not stated not stated
Stefan et al., 1999 9/69 (13%) not stated not stated
Wild et al., 1999 29/99 (29%) 17/45 (38%) 12/54 (22%) 
Total 330/836 (39%) 57 /148 (39%) 29/165 (18%)
(95% CI 36%-42%) (95% CI 31-47%) (95%CI 12-24%)
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2.4.2.4 Risk factors for vigabatrin-associated visual field defects 
The duration of VGB therapy before the occurence of the visual field defect has varied considerably.
In different studies, VGB therapy has been continued for from six weeks  to 180 months before the
visual field loss has been diagnosed (Eke et al., 1997, Arndt et al., 1999a, Daneshvar et al., 1999,
Lawden et al., 1999, Miller et al., 1999, Schmitz et al.,1999, Wild et al., 1999, Wohlrab et al., 1999,
Manuchehri et al., 2000, Midelfart et al., 2000, Rebolleda et al., 2000, Hardus et al., 2000a, 2001a).
The cumulative prevalence seems to reach a maximum at about 3 to 4 years, after which it plateaus.
An evaluation of a cohort of epilepsy patients exposed to VGB (Wild et al., 1999) revealed a
prevalence rate for visual field defects of 32% (95% CI 17%-47%) in patients who had received
VGB for less than 4 years (12 of 39) and 28% (95% CI 17%-39%) in those who had received
vigabatrin for over 4 years (17 of 61). In a cohort of 155 epilepsy surgery candidates, a visual field
defect was found in 19 out of 99 (19%) patients who were exposed to VGB before the examination
(Malmgren et al., 2001). The VGB recipients who had visual field defects, had been treated with
VGB significantly longer (52 months) than those who had no defects (14.6 months, p < 0.001). In
another study on epilepsy surgery candidates (Hardus et al., 2000a ), the loss of visual fields was
significantly more extensive in patients who had used VGB for 2-4 years or 4-6 years than in patients
who had used VGB for 0-2 years.
The correlation between the daily or cumulative dose of VGB and the risk of visual field
defects has been investigated in several studies. Wild et al. (1999) did not find any correlation, while
Manuchehri et al. (2000) showed that a significant correlation (p = 0.002) existed between the
severity of the visual field defect and the total dose ingested. Moreover, it has been found that the
total amount of ingested VGB is the most significant parameter to predict visual field loss (Hardus et
al., 2001a, Malmgren et al., 2001). The association between the cumulative incidence of visual field
defect and cumulative dose has also been evaluated by the Marketing Authorization Holders in a
cohort of 291 patients (CPMP-report/1999); the prevalence of visual field defects in this cohort was
30.2%. A steep increase in the cumulative incidence was found within the first 2 kg of VGB intake.
Incidence appeared to plateau after a total of 3kg of VGB intake (i.e. 3g/day for 3 years).
Male gender has been associated with an increased risk for VGB-associated visual field defects
in several studies (Wild et al., 1999, Hardus et al., 2000a, 2001a).  In the Marketing Authorization
Holders cohort, a positive association was found for male gender, with a cumulative incidence ratio
of 1.9 (CI 1.4-2.7) (CPMP-report/1999). The prevalence of visual field defects in either gender is
stated in 5 of  the published studies in adult epilepsy patients. A clear risk for male gender can be
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found on the basis of these data; visual field defects were found in 57 of 148 males (39%, 95% CI
31% to 47%) compared with 29 of 165 females (18%, 95% CI 12% to 24%), (Table 2).
2.4.2.5 Visual field defects in children treated with vigabatrin
In pediatric patients, the criteria for concentric visual field defect are even more confusing than in
adults. Both kinetic and static perimetries have been examined in cooperative patients but no clear
definition for abnormality have been presented (Wohlrab et al., 1999, Gross-Tsur et al., 2000,
Iannetti et al., 2000, Luchetti et al., 2000, Russell-Eggitt et al., 2000). The method used may vary
even within one study (Gross-Tsur et al., 2000). Although there are studies concerning the normality
of visual fields in children (Whiteside, 1976, Myers et al., 1999), the developmental age and possible
neurological and psychological conditions of the pediatric epilepsy patients have to be taken into
account in the interpretation of perimetry results. As there are always children who cannot perform
perimetry reliably, the study population is always more or less selected. It has even been speculated
that the use of VGB in children and adolescents might have a lower risk for visual field defects
(Rintahaka et al., 2000).
The prevalence rates in the pediatric series are presented in Table 3.  In addition, three pediatric
case reports with VGB-associated visual field defects have been published (Versino et al., 1999,
Vanhatalo et al., 1999). There is no information on the possible occurrence of visual field defects in
children who have been exposed to VGB in utero. During the development of the fetus, it has been
suggested that GABA acts as a trophic agent in retinal maturation (Crook and Pow, 1997, Hu et al.,
1998).
39
Table 3. Prevalence of VGB-associated visual field defects in pediatric patients.
Brigell et al., 2000 14/63 (22%)
Gross-Tsur et al., 2000 11/17 (65%)
Iannetti et al., 2000 4/21 (19%)
Luchetti et al., 2000 8/13 (62%)
Rintahaka et al., 2000 4/53 (8%)
Russell-Eggitt et al., 2000 10/14 (71%)
Vanhatalo et al. (Unpublished) 17/91 (19%)
Vecchio et al., 2000 2/8 (25%)
Wohlrab et al., 1999 5/12 (42%)
Total 75/292 (26%)
(95% CI 21% - 31%)
2.4.2.6 Prognosis of vigabatrin-associated visual field defects 
One of the criteria for a drug-induced adverse event is recovery upon withdrawal of the causative
drug. Thus, the question has been raised whether visual field defects are reversible after cessation of
the VGB therapy. The initial report by Eke et al. (1997) suggested that VGB-attributed visual field
defects are not reversible, and most studies thus far support their claim (Wong et al., 1997, Ruether
et al., 1998, Arndt et al., 1999b, Johnson et al., 2000, Harding et al., 2000b, Llerda et al., 2000,
Schmidt et al., 2000, Paul et al., 2001, Malmgren et al., 2001). In a long-term evaluation of VGB-
associated visual field loss, Hardus et al. (2000b) compared the visual field constriction in 16 patients
who had already stopped VGB medication before the first examination with that in 11 patients who
still continued VGB medication. In the follow-up, the concentric contraction did not change in this
selected group of patients, suggesting that VGB-associated visual field loss is not reversible. 
Five patients (two of whom were children) in four case reports have shown a recovery in visual
field constriction after withdrawal of VGB (Versino et al., 1999, Iannetti et al., 2000, Giordano et al.,
2000, Krakow et al., 2000). The authors suggested that young age may be a favorable factor in the
recovery, as repair mechanisms for retinal damage are more efficient in young people than in adults.
However, in the report by Versino et al. (1999), only one abnormal chart was obtained from the
patient and the second evaluation revealed normal visual fields, so it is also possible that the first
evaluation had revealed a false positive result and the second evaluation revealed a true negative
result or was an artifact or a learning effect. Experience in the evaluation of both unpublished
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pediatric series from Finland indicates that as many as 60% of first abnormal visual field results
change to normal when the perimetry is repeated (Rintahaka et al., 2000, Vanhatalo, et al. 2001). In
addition, recovery in visual fields has been observed after the early detection and withdrawal of the
drug in an individual case (Krämer et al., 2000). Some improvement in visual functions has also been
reported in single cases after discontinuation of VGB treatment (Lawden et al., 1999, Johnson et al.,
2000, Newman et al., 2000, Rintahaka et al., 2000). On the other hand, Wild et al. (1999) have
estimated on the basis of cumulative prevalence rates that visual field loss seems not to increase with
continuous VGB treatment beyond 4 years.
2.4.3 Contrast and glare sensitivity
The effects of GABAergic agents on visual perception were of interest before the issue of VGB-
associated visual field constriction raised concern. In healthy volunteers, a single oral dose of 2-3 g
VGB had no effect on spatial contrast sensitivity (Tiel-Wilck et al., 1995, Steinhoff et al., 1997a). In
epilepsy patients on CBZ monotherapy, recovery of impaired contrast sensitivity was observed after
a combination of VGB as add-on therapy (Sartucci et al., 1997). However, Sartucci et al. (1997)
found that contrast sensitivity in epilepsy patients treated with any AED was lower than that in
normal controls. In a recent study, Hilton et al. (2001) reported abnormal contrast sensitivity results
in 6 out of 11 (54.5%) epilepsy patient treated with current or previous VGB therapy. In pediatric
patients with VGB-associated visual dysfunction, loss in contrast sensitivity function has been found
with objective evaluation with the sweep VEP (Perron et al., 2001).
Abnormal glare sensitivity  has not been observed in epilepsy patients treated with VGB
therapy (Bayer, 1991), although in a clinical VGB vs CBZ study, scintillation was reported
significantly more in the VGB group that in the CBZ group (Kälviäinen et al., 1995).
2.4.4 Color vision
As retinotoxicity has been suggested to cause VGB-associated visual field defects, it is not surprising
that color vision has been examined by several investigators, but earlier studies have also been
published  concerning VGB´s influence on color vision. Single doses of VGB have been reported to
not affect color perception in healthy volunteers in two studies (Tiel-Wilck et al., 1995, Steinhoff et
al., 1997a), but Mecarelli et al. (2001) found a blue color vision defect in healthy volunteers after a
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single dose of 2g VGB. In the thesis by Bayer (1991), five out of eight  (63%) patients with VGB
add-on therapy had abnormal high total error scores in the FM100 Hue test, and two of them (25%)
had a blue axis. Recently, a study was presented where 5 out of 11 (45.5%) epilepsy patient treated
with current or previous VGB therapy were found to have abnormal hue perception with the FM100
Hue test (Hilton et al., 2001). Most of the published color vision results have been obtained with only
pseudoisochromatic plates, but Panel D-15 arrangement tests have also been used, infrequently. Both
normal (Lawden et al., 1999) and abnormal (Johnson et al., 2000, Manuchehri et al., 2000) color
perception have been revealed with Ishihara pseudoisochromatic plates in patients with VGB
associated visual field defect. Miller et al. (1999) found significantly decreased color perception in 19
out of 32 (59%) VGB patients compared with controls by AO-HRR plates, while Krauss et al.
(1998) revealed normal color vision with the same method  in 4 patients with VGB-associated visual
field defects. More recently, Paul et al. (2001) found abnormal color vision with AO-HRR plates in
5 (23%) of 22 epilepsy patients on VGB add-on therapy, but no deterioration during one-year
follow-up. Normal color vision examined with Panel D-15 (Ruether et al., 1998) and with
Desaturared Panel D-15 (Besch et al., 2000) has been reported in epilepsy patients with VGB-
associated visual field constriction. In addition, normal color vision has been reported in some
studies, but without information about the method used (Daneshvar et al., 1999, Newman et al.,
2000, Benozzi et al., 2001).
2.4.5 Dark adaptation
In the studies published so far, dark adaptation thresholds have been found to be within normal
ranges in patients with VGB-associated visual field defects (Bayer, 1991, Ruether et al., 1998, Besch
et al., 2000).
2.4.6 Ophthalmological findings
In most studies and case reports concerning VGB-attributed visual field defects, visual acuities (VA)
have been reported as normal (Eke et al., 1997, Krauss et al., 1998, Ruether et al., 1998, Daneshvar
et al., 1999, Hardus et al., 2000a, Iannetti et al., 2000, Newman et al., 2000, Russell-Eggitt et al.,
2000, Paul et al., 2001). Subnormal VAs have been reported by Miller et al. (1999); the subsequent
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follow-up after stopping the drug revealed slight improvement in them (Johnson et al., 2000).
Nonspecific retinal abnormalities including retinal arterial narrowing, epiretinal membrane formation,
irregular sheen, abnormal pigmentation or RPE abnormalities have been reported (Krauss et al.,
1998, Lawden et al., 1999, Miller et al., 1999, Wild et al., 1999). The most frequently reported single
ophthalmic sign is optic disc pallor (Eke et al., 1997, Wilson et al., 1997, Wong et al., 1997,
Daneshvar et al., 1999, Lawden et al., 1999, Wild et al., 1999, Ponjavic et al., 2000, Buncic et al.,
2001, McDonagh et al., 2001).
2.4.7 Electrophysiological changes
2.4.7.1 Visual evoked potentials 
A major problem in the clinical development of VGB was intramyelinic edema, which was found in
animals after VGB exposure (Gibson et al., 1990). In dogs, these changes were associated with
reversible increase in the latency of visual- and somatosensory-evoked potentials (Schroeder et al.,
1992). As a result, clinical studies regarding the potential changes in central conduction time in visual
pathways were subsequently carried out in epilepsy patients treated with VGB. These evaluations did
not reveal any drug-induced detrimental effect on human VEPs (Mervaala et al., 1989, Kälviäinen et
al., 1995, Harding et al., 1995 and 2000b, Mauguiére et al., 1997, Guberman et al., 2000). In patients
with VGB-associated visual field defects, most of the VEP recordings have been normal, suggesting
that the primary lesion is unlikely to be within either the visual pathways or visual cortex (Eke et al.,
1997, Krauss et al., 1998, Ruether et al., 1998, Lawden et al., 1999, Wild et al., 1999, Harding et al.,
2000b, McDonagh et al., 2001). However, reduced amplitudes and incresed latencies have been
found in individual patients (Krauss et al., 1998, Daneshvar et al., 1999, Miller et al., 1999). In a
study evaluating pediatric patients receiving VGB, five out of eleven (45%) epilepsy patients who
underwent VEP examination had prolonged latencies; all these patients had visual field defects
(Gross-Tsur et al., 2000). In a study by Zgorzalewicz et al., (2000) of pediatric patients treated with
VGB as add-on treatment, VEP abnormalities were observed in 10-20% of young epilepsy patients
with CBZ or VPA monotherapy, and add-on therapy with VGB did not increase the percentage of
pathological results. However, it has to be remembered that conventional pattern VEP only evaluates
the central 10o of the visual field and may miss more peripheral dysfunction.
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2.4.7.2 Electroretinogram 
Electroretinograms have been shown to be affected by the GABAergic system in  animals (Massey et
al., 1982, Kupenova et al., 1991, Arnarsson and Eysteinsson, 1997, Horiguchi et al., 1998, Plazonnet
et al., 2001). The effect of VGB on ERG has also been shown in healthy volunteers; administration
of a 1 to 2 g daily dose of VGB in a 10-day period increased significantly the latency of photopic b-
wave in such groups compared with CBZ and placebo groups, but no changes in oscillatory
potentials were observed (Harding et al., 1999). After the drug was stopped, the measurements
became normal again. Thus, the retinal electrophysiology associated with VGB has been found to be
complex. Harding et al. (2000a) suggested that the changes in the ERG may be unrelated to the
presence of visual field loss, and improved after withdrawal of the drug. Also in another study, the
photopic b-wave has been shown to be affected by current VGB therapy rather than by the visual
field loss, and to represent normal physiologic effects of elevated retinal GABA (Duckett et al.,
1998). In pediatric epilepsy patients, Westall et al. (2000) found significant reduction in oscillatory
potentials after six months VGB therapy in patients without VGB during initial examinations,
whereas patients on VGB at the time of the initial visit showed no progression in ERG responses
between the first and follow-up visits. A six-week period of VGB add-on treatment caused a delay in
b-wave, reduction in b-wave amplitude and marked reduction in oscillatory potentials as compared
with pretreatment results in 36 of 140 pediatric patients with refractory epilepsy (Duckett et al.,
1998). In the follow-up,  progression of the ERG abnormalities was seen in 78 out of 171 (46%)
patients (Brigell et al., 2000). The authors suggested that there are two effects of VGB on the ERG:
an early physiologic effect of elevated retinal GABA, and a progressive effect on the outer retina,
which implies a risk of associated visual field defect.
Abnormalities in ERGs have been identified since the publication of the earliest reports of
VGB-attributed visual field defects. Typical changes are increases in photopic b-wave latencies,
reduction of the b-wave amplitude, and markedly reduced or absent oscillatory potentials, suggesting
inner retinal damage involving Müller cells (Bayer, 1991, Eke et al., 1997, Krauss et al., 1998,
Ruether et al., 1998, Arndt et al., 1999a, Daneshvar et al., 1999, Miller et al., 1999, Wild et al., 1999,
Gross-Tsur et al.,  2000, Coupland et al., 2001, Hardus et al., 2001b, McDonagh et al., 2001). In
several studies (Miller et al., 1999, Harding et al., 2000a,b, Coupland et al., 2001, Ponjavic and
Andréasson, 2001), the most consistently occurring  electrophysiologic variance with VGB
associated visual field defects was the 30-Hz flicker cone wave amplitude. Harding et al. (2000a,b)
concluded that the measurement of the amplitude of the cone flicker response is sufficiently sensitive
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(100%) and specific (75%) for VGB associated visual field defects that it can be used to screen
patients in whom perimetry cannot be reliably performed. On the other hand, Hardus et al. (2001b)
showed that electrophysiology does not appear to be a good method to detect patients with, or at risk
of, VGB-associated visual field loss. In multifocal ERGs, marked reduction in peripheral parts of the
stimulated area has been observed (Lawden et al., 1999, Harding et al., 2000b, Johnson et al., 2000,
Ponjavic and Andréasson, 2001, McDonagh et al., 2001).
A correlation has been found between the ERG changes and the duration of VGB therapy
(Gross-Tsur et al., 2000, Herbert et al., 2000, Coupland et al., 2001, Hardus et al., 2001b), and
between the ERG abnormalities and the severity of the visual field defects (Miller et al., 1999,
Harding, 2000a, Hardus et al., 2001b). Mild reversal of ERG changes after discontinuation of VGB
has been reported in individual patients by Johnson et al. (2000) and Krakow et al. (2000).   
2.4.7.3 Electro-oculogram 
Reduction of the Arden Index in the EOGs has been found in the evaluation of  patients with VGB
attributed visual field defects (Eke et al., 1997, Krämer et al., 1997, Arndt et al., 1999a, Daneshvar
et al., 1999, Laplace et al., 2000, Coupland et al., 2001), but normal EOGs have been reported as
well (Harding et al., 2000b, McDonagh et al., 2001). Epilepsy patients with current VGB therapy but
without visual field defects have shown altered Arden Index or EOG amplitudes, possibly indicating
more the efficacy than the toxicity of the drug  (Rebolleda et al., 2000, Laplace et al., 2000, Harding
et al., 2000a). It has also been noticed that the Arden Index was significantly reduced in patients who
were taking VGB at the time of EOG examination, while patients who had previously been exposed
to VGB, but had discontinued the drug before EOG examination, showed nearly normal results
(Lawden et al., 1999, Coupland et al., 2001).  
2.5 The influence of tiagabine on the visual system
2.5.1 Retina
In isolated animal retinas, a GABA uptake blocker, nipecotic acid, the analog of which is TGB, has
been found to affect photopic ERG and intracellular potentials of horizontal cells (Massey et al.,
1982, Perlman and Norman, 1990, Arnarsson and Eysteinsson, 1997). Recently, Sills et al. (2001)
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have found that TGB, in doses of 5, 10 or 20 mg/kg, has no effect on GABA concentrations or on
the activity of GABA-T in the rat retina. Unlike VGB, TGB has not been found to accumulate in the
rat retina (Sills et al., 2001).
2.5.2 Visual fields
Visual symptoms such as dose-related transient nystagmus and blurring of vision but no visual field
defects have been reported  in clinical TGB trials ( Leppik et al., 1999, Fakhoury et al., 2000a). In an
evaluation by Collins et al. (1998), incidence data from all phase II and phase III clinical TGB trials
were examined for adverse events potentially relating to visual field defects. Eight patients (0.3%) out
of 2531 had complaints which might be ascribed to visual field changes; two patients had localized
visual field defects from earlier brain lesions and six had transient visual disturbances. Three of the six
symptoms resolved without intervention, and three others after reduction of TGB or concomitant
AED dosage. The shortcoming of this evaluation is that the visual field testing was performed only
with confrontation.
As an other GABAergic AED, progabide, was reported to affect visual fields in a similar
manner to that of  VGB (Baulac et al., 1998), TGB as well as other AEDs with GABAergic
mechanisms of action became questionable (Rao et al., 1998, Beran et al., 1998, 1999). Only two
reports have presented visual field defects associated with TGB treatment. Beran et al. (1998, 1999)
reported that 6 patients out of 12 on TGB had asymptomatic visual field constriction. Their results
have been published only in abstract form and the clinical details of the patients, for instance the
possible earlier use of VGB, have not been reported. Kaufman et al. (2000) have published one case
report about a reversible visual field loss associated with TGB treatment. They presented a
psychiatric patient who was examined with repeated automated perimetries after 12 and 18 months
exposure to TGB, and after discontinuation of the drug. In the Full Field 120-point test, there were
initially 7/120 (right eye) and 1/120 (left eye) absolute defects, increasing during the follow-up to
9/120 and 6/120. After the drug had been stopped, the number of missing points gradually decreased
to 7/120 and 3/120.
A few evaluations presenting negative results have been published regarding TGB and visual
field defects. Kinetic Goldmann and automated Humphrey perimetries did not reveal visual field
constrictions in 8 epilepsy patients treated with TGB (Fakhoury et al., 2000b).  Preliminary results of
a multicenter study on epilepsy patients receiving TGB monotherapy and matched controls receiving
CBZ or lamotrigine monotherapy have been published as a congress abstract (Kälviäinen et al.,
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2000). In that paper, no concentric visual field defects were found in 28 patients treated with initial
TGB monotherapy. The mean daily dose was 15.9 mg (range 10-20 mg) and the mean treatment
duration 26.3 months (range 3-58 months). Both Goldmann and Humphrey perimetries were used in
this study.
2.5.3 Visual function tests
The above-mentioned evaluations and case reports regarding visual functions in epilepsy patients
treated with TGB did not present records relating to color vision, contrast or glare sensitivity, dark
adaptation or electrophysiology. 
2.6 The influence of carbamazepine on the visual system
Carbamazepine may cause ophthalmic adverse effects which are considered to originate at the level
of the brainstem and cerebellum (Mattson, 1998). The ocular adverse effects of CBZ involve mainly
the extraocular muscles, causing diplopia and nystagmus as a symptom (Zaccara et al., 1992), but
accommodative problems can occur as well. Because of these various neurotoxic effects of CBZ,
many investigators have become interested in the effects of CBZ on visual functions. 
2.6.1 Retina
The possible retinotoxic effect of CBZ has been suggested by Vesti Nielsen and Syversen  (1986).
They presented two patients with epilepsy and with more than seven years of CBZ therapy who
developed decreased visual acuity and paracentral scotoma. Both had retinal pigment epithelial
changes in the ophthalmoscopy and fluorescein angiography. The changes were reversible after
cessation of CBZ. As CBZ is widely used in the treatment of epilepsy as well as in other neurological
conditions, it is obvious that the retinotoxic effect of CBZ is rather uncommon.
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2.6.2 Visual fields
Slight concentric constriction of visual fields has been reported in epilepsy patients treated with CBZ
(Zrenner and Nowicki, 1985), and patients with possible CBZ-associated retinopathy had either
normal visual fields or paracentral scotoma (Vesti Nielsen and Syversen, 1986). In the thesis by
Bayer (1991), patients with CBZ monotherapy were found to have normal visual fields with
automated Octopus perimetry. Only one patient with combination therapy with CBZ, DPH and
phenobarbital had concentric visual field loss: the author suggested that the cause was DPH.
2.6.3 Contrast and glare sensitivity
Epilepsy patients with long-term CBZ monotherapy showed impaired contrast sensitivity in all
examined spatial frequencies (0.5 to about 20 cpd) in two controlled studies (Tomson et al., 1988,
Sartucci et al., 1997), while Paulus et al. (1996) and Steinhoff et al. (1997b) found no alterations in
perception thresholds for sinusoidal gratings in epilepsy patients receiving CBZ monotherapy. A
single oral dose of 400 mg CBZ has been found not to change spatial contrast sensitivity in healthy
volunteers (Tiel-Wilck et al., 1995, Steinhoff et al., 1997a). 
Bayer (1991) and Bayer et al. (1991a,b and 1995a,b) have investigated mesopic vision in
epilepsy patients using a Rodenstock-Nyktometer with and without glare. They found that mesopic
vision and especially glare sensitivity in dim circumstances were markedly affected in epilepsy patients
treated with CBZ monotherapy compared with normal controls.
2.6.4 Color vision
A single oral dose of 400 mg CBZ in healthy volunteers has been found not to affect color vision
measured with the desaturated Lanthony 15 test (Steinhoff et al., 1997a), whereas non-standardized
color VEP and color perimetry tests revealed mild impairment in both red and blue chromatic systems
(Mecarelli et al., 2001). In epilepsy patients with long-term CBZ monotherapy, acquired color vision
defects, i.e. high total error scores and blue axes, have been found with the FM100 Hue test (Zrenner
and Nowicki, 1985, Bayer, 1991, Bayer et al., 1991b, Bayer et al., 1995 a,b, Paulus et al., 1996,
1997). However, Steinhoff et al. (1997b) found no significant color vision defects with the
Desaturated Lanthony 15 test in CBZ monotherapy patients. Recently, the FM100 Hue test revealed
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significant abnormalities in color perception, mainly in the blue-axis, in 8 out of 12 (67%) patients on
CBZ monotherapy (López et al., 1999). In a study by Bayer et al. (1997), newly diagnosed epilepsy
patients who were treated with initial CBZ monotherapy developed blue-yellow color vision defects
in the FM100 Hue test during a follow-up period of 18 months. These defects were also found with
the Tritan Screening Plates. On the other hand, the patients with possible CBZ-induced retinopathy
had normal color vision with the Ishihara and AO-HRR tests (Vesti Nielsen and Syversen, 1986).
2.6.5 Dark adaptation
Only a few reports, all of which reported normal dark adaptation curves, have been published
concerning dark adaptation during CBZ therapy (Zrenner and Nowicki, 1985, Vesti Nielsen and
Syversen, 1986, Bayer, 1991, Bayer et al., 1995a). 
2.6.6 Electrophysiological changes
Significantly prolonged VEP latencies reflecting slowing in impulse conduction have been reported
in epilepsy patients receiving CBZ monotherapy as compared with patients on VGB monotherapy
(Mervaala et al., 1989, Kälviäinen, 1992, Kälviäinen et al., 1995). In his thesis, however, Bayer
(1991) found normal VEP latencies in all patients on CBZ who underwent VEP examination.
Harding et al. (1999) examined the effects of an increasing dose of 400 to 800 mg CBZ over a period
of 10 days on ERG and EOG in healthy volunteers. Neither ERG nor EOG changed significantly
when measured at the baseline and on days two, four and nine. 
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3 AIMS OF THE STUDY
In 1997, three cases of severe symptomatic and persistent visual field constriction associated with
VGB treatment were described (Eke et al., 1997). During the period 1997 to 1998, similar concentric
visual field constrictions were reported in symptomatic and asymptomatic patients with drug-resistant
epilepsy. Most patients had refractory epilepsy and also used other AEDs as polytherapy, and a
causal relationship between visual field defects and VGB treatment was not established. The
electrophysiological changes reported in these patients suggested retinal damage as a mechanism of
the visual field defects (Krauss et al., 1998).
The aim of the present series of studies (I-V) was to answer the following questions:
1. Is there a causal link between AED therapy with VGB and concentric visual field 
defects? (I) 
a) What is the prevalence of VGB-associated visual field defects? (I, II)
b) Are VGB-associated visual field defects reversible after discontinuation of the
 drug, or progressive with continued therapy? (II) 
c) Are there risk factors for VGB-associated visual field defects? (I, II) 
d) Are VGB-related visual field defects associated with impairment in visual 
function, such  as contrast and glare sensitivity or color vision? (III, IV)
2. Are concentric visual field defects a class effect of GABAergic antiepileptic 
drugs? (V)
3. What is the influence of AED monotherapy with TGB or CBZ on visual function? 
(III, IV, V)
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4 PATIENTS AND METHODS
4.1 Study design
The present study consists of five original publications, four of which are cross-sectional comparative
clinical trials (I,III-V) and one of which is a follow-up study (II). Clinical examinations were carried
out at the Departments of Ophthalmology, Neurology, Neuroradiology and Clinical Neurophysiology
in Kuopio University Hospital and at the Department of Ophthalmology in Turku University Hospital
during 1997-2000. All ophthalmological examinations were carried out by the author, excluding the
automated perimetry in study V and the neuro-ophthalomological examination on 8 patients in Turku
University Hospital in study I.
4.2 Patients 
During the years 1988-95, 135 patients with newly diagnosed partial epilepsy had been randomly
assigned to either VGB or CBZ monotherapy groups in the Department of Neurology in Kuopio
University Hospital for a comparative VGB vs. CBZ monotherapy study (Kälviäinen, 1992,
Kälviäinen et al., 1995). For the present cross-sectional studies (I, III, IV) and for a part of the
follow-up study (II) we identified 32 patients on VGB and 18 patients on CBZ still successfully using
their study treatment as monotherapy and attending the outpatient Department of Neurology in
Kuopio University Hospital. The two groups were found to be comparable in terms of demographic
data. Three additional VGB monotherapy patients were identified for the follow-up study (II). 
Most of the VGB monotherapy patients, i.e. 29 out of 35 had VGB as their initial treatment,
but six patients who had switched to VGB monotherapy after failure with conventional AED
monotherapy were also investigated. The  patient population in the follow-up study (II) consisted of
all cooperative patients in the outpatient department of neurology who had used VGB as
monotherapy or as add-on treatment for at least 6 months irrespective of their individual decision
whether to continue the treatment or not. All patients treated with VGB received oral and written
information about VGB-related visual field defects at the time when the risk was discovered.
Participation in the study did not influence their treatment choice. In clinical practice we followed up
some of the VGB patients (especially those who continued with VGB) every six to twelve months.
The TGB monotherapy group comprised a subgroup of 40 epilepsy patients, who had
converted to TGB monotherapy during the years 1995-1997. They had had either unsatisfactory
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seizure control and/or unacceptable adverse effects with their earlier AED monotherapy. Fifteen
patients out of 16 still continuing with TGB monotherapy were examined. One patient was excluded
due to bilateral cataracts. One patient treated with TGB monotherapy had optic nerve atrophy and
homonymous hemianopsia; he was excluded from statistical analyses and from contrast sensitivity and
color vision studies.
Seventeen of the 18 CBZ monotherapy patients had CBZ as their initial treatment but one
patient did not respond to VGB monotherapy during the titration phase and was switched to CBZ as
her second monotherapy. The plasma concentration of CBZ was whitin the reference range (20-50
µmol/l) in all patients.
All patients were outpatients who suffered from partial epilepsy with or without secondary
generalization. The patients with VGB, TGB and CBZ monotherapy and 11 of the patients with VGB
add-on therapy were seizure-free or satisfactorily controlled with therapy. In the add-on group, there
were 14 patients who had refractory epilepsy with continuous seizures despite drug therapy. Normal
general intelligence had been confirmed with formal neurophsychological tests in VGB, TGB and
CBZ monotherapy  patients (Kälviäinen et al., 1995, Kälviäinen et al., 1999).
Table 4. Number of patients and controls in studies I-V.
Study I Study II Study III Study IV Study V
VGB monotherapy 32 35 32  32
VGB add-on therapy 25
TGB monotherapy  15
CBZ monotherapy 18 18 18
Controls 18 18 47 35 18 VF, 35 CS
VF visual fields, CS contrast sensitivity
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Table 5. Demographics and characteristics of the epilepsy patients in studies I-V (mean ± SD).
VGB VGB TGB CBZ
monotherapy add-on therapy monotherapy monotherapy
Number of patients 35 25 15 18
Age (years) 41 ± 16 40 ± 13 52 ± 12 44 ± 18
Range 20 - 74 17 - 62 31 - 71 20 - 70
Female, n 21 14 9 12
Male, n 14 11 6 6
Daily dose 2.7 ± 0.6 g 2.6 ± 0.6 g 21 ±13 mg 719 ± 172 mg
Range 2 - 4 g 1 - 5 g 5 - 60 mg 400 - 1000 mg
Cumulative dose 6 ± 3.6 kg 3.8 ± 4.0 kg 25 ± 17 g
Range 1.8 - 18.7 kg 0.42 - 18.0 kg 4.5 - 68 g
Duration of the 
therapy (months) 70 ± 30 49 ± 36 38 ± 10 61 ± 26
Range 29 - 120 7 - 168 23 - 55 32 - 108
Etiology of epilepsy
Cryptogenic, n 23 13 8 15
Symptomatic, n  12 12 7 3
4.3 Controls  
Over several years, we have investigated under standardized conditions normal values of visual
function tests for different age groups in the Department of Ophthalmology in Kuopio University
Hospital. Of these source data, we selected results of all age- and gender-matched normals for the
statistical analyses of FM100 total error scores (Mäntyjärvi, 2001) and contrast sensitivity results in
the studies III-V (Mäntyjärvi and Laitinen, 2001). The normal controls for Goldmann perimetry were
examined especially for this study. The healthy volunteers comprised staff and outpatients in the
Department of Ophthalmology in Kuopio University Hospital and, students in the University of
Kuopio. All controls were interviewed in order to exclude those with ophthalmological disorders.  
4.4 Approval of the Ethics Committee
The study was approved by the Ethics Committee of Kuopio University Hospital and the University
of Kuopio. Informed  written consent was obtained from the patients. 
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4.5 Ophthalmological examination (I-V)
The clinical examination included determination of the best corrected VA, measurement of the
intraocular pressure with the Goldmann applanation tonometry, assessment of ocular motility,
alignment and pupillary reactions, biomicroscopy of the anterior segment, and fundus examination
using non-contact fundus lenses (Volk 90 or Volk Superfield), and a three-mirror contact lens when
needed.
Best corrected VA was measured at 5 meters with a Nikon chart projector. The results were
also converted to LogMAR acuities (Ferris et al. 1982). Refraction was determined using retinoscopy
with both normal-sized and dilated pupils. The presence of phorias and tropias was assessed at
distance (5m) and at near (30cm), and motility, convergence and pupillary reactions were observed.
Dilatation of the pupils was induced with tropicamide 0.8% + phenylephrine 5% drops. 
4.6 Visual fields
4.6.1 Kinetic perimetry (I, II, V)
Visual fields were examined in a dark room, the right eye first followed by the left eye, with the
standard manually operated kinetic Goldmann perimeter (Haag-Streit, Bern, Switzerland). White test
stimuli, Goldmann size of IV (16mm ) and I (0.25mm ) with a background luminance of 31.52    2
apostilbs (10 candela/m ) were used. The light intensity of the target was 4 (1000 apostilb) in2
examining the peripheral isopter with stimulus IV, and 3 (315 apostilb) in examining the central
isopter and the blind spot with stimulus I. Before the examination, the calibration of the perimeter
was done according to the instructions of the manufacturer. Patients had normal-sized pupils and
intraocular pressure was measured after the visual field examination. Peripheral field was examined
without corrective lenses but age-dependent near vision correction was added to the distance
correction in patients over 40 year old when the central part of the visual field was examined.
Prior to the examination, patients adapted to the background illumination for 2 to 3 minutes.
During the examination, the stimulus was moved from the periphery to the centre of the visual field
with a speed of about 2-5o per second. All meridians spaced every 15o were examined. The fixation
was observed during the examination through a checking device. The writer performed all kinetic
visual field examinations, masked for the treatment group in study I. To confirm the results, eight
patients from the VGB monotherapy group (2 with severe constrictions, 5 with mild constrictions and
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1 with normal visual fields) were checked by an experienced neuro-ophthalmologist, professor Eeva
Nikoskelainen in Turku University Hospital without knowledge of  previous visual field findings.
The results of the Goldmann perimetry were estimated  using an empirical semi-quantitative
procedure: a visual field (isopter IV/4) extending over 70o temporally was considered as normal
(Galan, 1968, Egge, 1984), from 50o to 70o as mildly abnormal, and a visual field narrower than 50o
temporally as severely abnormal (Figure 3). The largest isopter (IV/4) was measured in degrees in the
cardinal meridians (i.e. temporal, nasal, superior and inferior) for the statistical evaluation. 
      normal visual field     
     mildly abnormal visual field
     severely abnormal visual field
Figure 3. The extents of the normal visual field (left eye) and the limits of mild and severe
defects used in this study.
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4.6.2 Static perimetry (V)
Automated static perimetry was performed with a Humphrey Field Analyser Mark 2 (HFA,
Humphrey systems, Dublin, CA) using the standard age-corrected Full Field 120 two-zone
suprathreshold strategy. The visual field out to 60o from the central fixation was examined. Near
vision correction was calculated using Humphrey´s internal algorithm and used when central visual
field was examined. Static visual field examinations were performed with normal-sized pupils and the
right eye was examined first, followed by the left eye. Static suprathreshold perimetry was considered
abnormal if three or more adjoining points were missed. 
4.7 Contrast sensitivity (III, V)
Contrast sensitivity was measured monocularly with the Pelli-Robson letter chart (Clement Clarke
International Ltd. Harlow, Essex, U.K.; Pelli et al., 1988, Rubin, 1988) under conditions of constant
illumination of 100 cd/m² (accepted range for the Pelli-Robson test from 60 to 120 cd/m²). The test
distance was 3 m, corresponding to the spatial frequence of 3 cpd. The patient’s own distance
correction or the best correction on trial frames were used. The logarithmic contrast sensitivity value
of the last triplet of which at least two letters were correctly seen was marked as the result. Normal
values published by Mäntyjärvi and Laitinen (2001) were used in assessing individual results.
4.8 Glare sensitivity (III)
Brightness acuity and macular photostress tests were performed monocularly with the Mentor BAT
(Marco Ophthalmic Inc., Jacksonville, Fla) in 32 VGB monotherapy patients and in 18 CBZ
monotherapy patients. With the device, it is possible to produce a full hemispherical light source at
a distance of 64 mm from the eye. In the BAT, the best corrected distant VA was measured without
glare and with low, intermediate and high glare (41, 342 and 1370 cd/m²) using the same high-
contrast projector in a dark room as in the normal VA testing. In the results, the worsening of two
lines in VA was accepted as normal. In the macular photo-stress test, consistent high glare (1370
cd/m²) was maintained for 15 s, and the length of time required for the VA to recover to two lines
above the line of the best corrected VA was recorded. The normal recovery time of 0 to 30 seconds
was used in assessing the individual results (Glaser et al., 1977). Both glare sensitivity examinations
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were made with normal-sized pupils without dilatation and with patients’ own distance correction or
with the best correction on trial frames.
4.9 Color vision (IV, V)
The color vision examination consisted of a battery of pseudoisochromatic plates, a hue
discrimination test, and metameric matches. The right and left eye were examined separately in a
random order, and near vision correction was used in all color vision tests when needed. The
illumination for SPP2 and FM100 Hue tests was provided by a Macbeth Easel lamp (Newburgh, NY,
U.S.), 1000 lux. Cases where ophthalmic disorders might have interfered with color vision were
excluded. 
4.9.1 Standard Pseudoisochromatic Plates 2
Standard Pseudoisochromatic Plates part 2 (SPP2, Ichikawa et al., 1983) are designed to detect both
acquired and congenital color vision defects (Tanabe et al., 1984, Ichikawa et al., 1987). The test
consists of 12 pseudoisochromatic plates, two of which are demonstration plates and the other 10 are
diagnostic plates with 5 red-green and 10 blue numbers. The testee passes the test if at least 5/5 red-
green numbers and 9/10 blue numbers are named correctly (Tanabe et al., 1984). 
4.9.2 Farnsworth-Munsell 100 Hue test
The color discrimination ability was examined with the FM100 Hue test. The error scores were
calculated according to Kinnear (1970), as square roots, and the age-dependent normal values of
Verriest et al. (1982) were used in assessing individual results. The normal values of Smith et al.
(1985) were used in assessing individual axes. Calculations were performed and diagrams were drawn
using FM Scoring Software Version 2.1 (Macbeth Division of Kollmorgen Corp., 1997). Because the
FM100 total error score is highly dependent on the age of the subject, the age was added as a
covariate in the statistical comparison of the FM100 results. Due to fatigue, one patient in the VGB
monotherapy group and one patient in the TGB monotherapy group performed the FM100 Hue test
only with one eye. 
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4.9.3 Color Vision Meter 712 anomaloscope
Metameric matches were investigated with a computer controlled electronic Color Vision Meter 712
anomaloscope (CVM 712, Interzeag, Schlieren, Switzerland) where red, green (Rayleigh equation)
and blue (Moreland equation) color vision was examined. The stimulus was presented for 2 seconds
on a bipartite field of 2o, with an achromatic field between the presentations to maintain the
adaptation level. The matching ranges (MR) and mid matching points (MMP) for both equations
were recorded, and the anomalous quotients (AQ) were calculated according to Birch et al. (1979).
In calculations we used the normal values examined earlier with the same instrument in our clinic
(Maaranen et al., 2000). Values from 0.7 to 1.3 in the Rayleigh equation and from 0.7 to 1.4 in the
Moreland equation were considered normal AQs, and values from 0 to 10 in the Rayleigh equation
and from 0 to 11 in the Moreland equation normal MRs.
4.10 Dark adaptation (III)
The dark-adaptation examination was done monocularly in the right eye with the Goldmann-Weekers
Adaptometer (Haag-Streit, Bern, Switzerland) according to the instructions for the absolute
threshold, and only the rod threshold was examined in both eyes. After a short adaptation in complete
darkness, the light-adaptation of cones was done in 5 minutes in the brightly illuminated sphere
before the dark-adaptation examination. The dark adaptation curve obtained is biphasic, with an early
rapid increase in cone sensitivity and a delayed slower increase in rod sensitivity. Values from 3.8 to
4.6 log units (mean 4.2 ± 0.2) for the cone threshold and from 5 to 9 min (mean 7 ± 1) for time, and
from 1.8 to 2.4 log units (mean 2.13 ± 0.15) for the final rod threshold and from 22 to 32 min (mean
27 ± 2.5) for time, were accepted as normal. These normal values were calculated in 51 normal
volunteers aged from 10 to 69 years at our clinic.
4.11 Electroretinogram (I)
Electroretinogram was performed on patients who had abnormal visual fields, to further evaluate the
pathogenesis of the defects. ERG was performed with a Nicolet Ganzfield stimulator according to the
recommended standards of the International Society for the Clinical Electrophysiology of Vision
(ISCEV) (Marmor et al., 1989, Celesia et al., 1993). Tropicamide 0.5% drops were used for dilating
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the pupils, and corneal contact lens electrodes were positioned after applying oxibuprocaine drops for
topical anesthesia. In accordance with the ISCEV standards, after the dark adaptation for at least 20
minutes, the rod response, maximal combined response, oscillatory potentials and cone response were
recorded.
4.12 Neuroradiology (I)
At the time of epilepsy diagnosis, CT or MRI examinations were performed to determine the etiology
of epilepsy in each patient. During study I, MRI was repeated in those VGB monotherapy patients
who had abnormal visual fields. The examinations were performed with a 1.5 T Magnetom Vision
(Siemens, Erlangen, Germany), special attention being paid to orbit, visual pathways, and occipital
lobes.
4.13 Statistical methods (I-V)
Statistical analysis was performed with the SPSS/PC Version 9.1 and 10.0 (Chicago, Ill.) and
Statview 512 + (Berkeley, CA) programs. The results of continuous variables are presented as means
± standard deviations (SD). The chi-square test was used to compare frequencies in different groups
and the two-tailed T-test to compare continuous parameters between two groups. The non-
parametric Mann-Whitney and Kruskall-Wallis tests were used when the number of observations was
less than ten. One-way analysis of variance (ANOVA) for independent observations with Scheffe’s
and LSD posthoc tests was used to compare more than two groups. The significance of the change
between two different measurements of the same parameter was tested with the paired T-test. Linear
regression was used to assess the correlation between parameters and clinical variables. The
confidence interval (CI) of 95% was calculated from important prevalences. P values of <0.01
(studies I and V) and <0.05 (studies II, III, IV) were considered significant. In individual assessment
of the results, the mean of the normals ± 2SD was considered the limit of normality.
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5 RESULTS 
5.1 History and visual symptoms (I-V)
The presence of visual symptoms and the history of previous ophthalmic diseases was elicited at the
beginning of the examination. None of the patients (I-V) or normal controls complained about
current visual problems before the examination, and none had diagnosis or suspicion of glaucoma or
ocular hypertension in the history. 
A 54-year-old male in the VGB monotherapy group had had a perforating injury in his right eye
in 1968. He had traumatic aphakia, and corneal and retinal scars. A 32-year-old female in the VGB
monotherapy group had congenital microphthalmos with pupil and lens abnormalities in her right eye.
In study V, one patient had previously been documented as having bilateral optic nerve atrophy
and homonymous hemianopia: the etiology of visual field defects was occipital infarct probably
caused by birth trauma. A 58-year-old man had undergone 4 years earlier bilateral focal
photocoagulation for peripheral retinal degeneration (20 burns per eye with energy of 180 mW, spot
size of 200 µm and exposure time of 0.1 sec). Four patients had undergone intra-cranial operations
for benign tumors or vascular abnormalities but they did not complain of any problems in seeing.
After the examination, the VGB patients with abnormal fields were again asked about
symptoms, but only two reported any; complaining about repeatedly bumping into people or
furniture, or stumbling over a cat. All other patients who had visual field defects were asymptomatic.
5.2. Ophthalmological findings (I-V)
5.2.1 Visual acuity
The VAs of patients are presented in Table 6. In the VGB monotherapy group, the patient with
aphakia had corrected VA  0.6 (LogMAR +0.2) in the affected eye, and the patient with
microphthalmos counted fingers with the affected eye. In the VGB add-on therapy group, one patient
with strabismic amblyopia had corrected VA 0.2 (LogMAR +0.4) in the affected eye. The VAs in the
patients treated with VGB did not change during the follow-up time. One way ANOVA with
Scheffe´s post hoc test did not reveal significant differences in visual acuities between the groups.
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Table 6. Visual acuities in patients treated with VGB, TGB or CBZ monotherapy or with
VGB add-on therapy (mean ± SD).  
Snellen Snellen LogMAR LogMAR
(RE) (LE) (RE) (LE)
VGB monotherapy 0.96 ± 0.078 0.97 ± 0.087 0.018 ± 0.039 0.017 ± 0.045
 (n = 33 RE, 35 LE)
Range (0.8 - 1.0) (0.7 - 1.0) (0- + 0.1) (0- + 0.1)
VGB add-on therapy 
(n = 25) 0.99 ± 0.177 1.02 ± 0.074 0.019 ± 0.141 -0.008 ± 0.027
Range (0.2 - 1.33) (1.0 - 1.33) (-0.1 - + 0.7) (-0.1 - 0)
CBZ monotherapy 
(n = 18) 0.96 ± 0.078 0.94 ± 0.086 0.033 ± 0.049 0.033 ± 0.049
Range (0.8 - 1.0) (0.8 - 1.0) (0- + 0.1) (0- + 0.1)
TGB monotherapy 
(n = 15) 0.97 ± 0.168 0.97 ± 0.183 0.027 ± 0.110 0.020 ± 0.115
Range (0.4 - 1.2) (0.4 - 1.2) (-0.1 - +0.4) (-0.1 - +0.4)
RE right eye, LE left eye
5.2.2 Alignment, motility and pupillary reactions
The patients with aphakia and amblyopia had manifest divergent squint, and some patients had non-
significant phorias. One patient on VGB monotherapy and one on CBZ monotherapy had undergone
earlier strabismic surgery, but neither of them currently had manifest squint. All patients had normal
pupillary reactions to light and convergence with the exception of restricted  reactions in the aphakic
and microphthalmic eye.
5.2.3 Biomicroscopy 
The two patients described above in the VGB monotherapy group showed changes in the anterior
structures of the eye on biomicroscopy. In the TGB group, one patient had slight nuclear sclerosis:
all others had clear lenses.
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5.2.4 Intraocular pressure 
Intraocular pressure was within normal ranges <21 mmHg in all patients. 
5.2.5 Ophthalmoscopy 
Slight pallor of the optic discs was found in 7 patients with VGB treatment: in 3 VGB monotherapy
patients and in 4 add-on patients. All these patients had severely constricted visual fields. Previously
documented optic nerve atrophy was found in one TGB monotherapy patient. None had
glaucomatous optic nerve cupping. The patient with a previous perforating injury had retinal scars in
the affected eye. Minor changes in the RPE (scars or defects near the macular area) were found in
two patients; one with VGB monotherapy, and one with TGB monotherapy. In addition, one patient
in TGB monotherapy group had minor laser-scars in the superior periphery of both eyes.
5.3 Visual fields
5.3.1 Kinetic perimetry (I, II, V)
In the clinical evaluation of the kinetic visual fields of monotherapy patients (Study I), 13 of 32
patients (40%, 95% CI 23%-57%) treated with initial VGB monotherapy had concentric visual field
constriction, whereas all patients treated with CBZ monotherapy and healthy controls had normal
visual fields. The defect was severe in 3 patients (9%, upper 95% CI 19%) and mild in 10 patients
(31%, 95% CI 15%-47%) treated with VGB monotherapy.
In the whole group of patients on VGB (study II), clinical evaluation  revealed concentric
constriction of the visual fields in 24 of 60 patients (40%, 95% CI 28%-52%). Severe constriction of
the visual fields was found in 8 patients with previous or present VGB medication (13%, 95% CI
9%-17%). Four of these had received VGB as monotherapy and four as add-on therapy. Mild
constriction was found in 16 patients (27%, 95% CI 21%-33%), 10 in the monotherapy group and
6 in the add-on group (Table 7).
Three patients treated with TGB monotherapy had localized defects, one homonymous
hemianopia and two quadrantanopias from earlier documented brain lesions. None in the TGB
monotherapy group had concentric visual field constriction. 
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Table 7. Clinical evaluation of the visual fields in patients treated with VGB  monotherapy or
add-on therapy (number of patients (%) with 95% CI).
Monotherapy Add-on therapy Total
n = 35 n = 25 n = 60
Visual fields
Normal, n 21 (60%) 15 (60%) 36 (60%)
Mildly abnormal, n 10 (29%) 6 (24%) 16 (27%)
(95% CI 21%-33%)
Severely abnormal, n 4 (11%) 4 (16%) 8 (13%)
(95% CI 9%-17%)
A significant difference was found between the groups in all cardinal meridians of the visual
field extents (one-way ANOVA; p < 0.0001 in all meridians). The differences between the groups
revealed by Scheffe’s posthoc test are presented in Table 8. Both the VGB monotherapy  and add-on
therapy groups showed a significant difference when compared with controls in all meridians of both
eyes. There was no significant difference between the right and left eye in visual field extents in any
group. Patients with localized visual field defects in the TGB group and one patient in the VGB add-
on group, due to unreliable performance in visual field examination, excluded from the statistical
analysis.
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Table 8. Visual field extents in degrees in the cardinal meridians (mean ± SD).
VGB VGB TGB CBZ Controls
monotherapy add-on therapy
 n = 33 RE, 35 LE n = 24 n = 12 n = 18 n = 18
Meridian
Right temporal 69 ± 12 *#§ 75 ± 15*# 86 ± 4 86 ± 5 89 ± 2
Range 40 - 90 38 - 90 78 - 90 70 - 90 82 - 90
Right superior 43 ± 6* 42 ± 8* 48 ± 3 46 ± 6* 53 ± 4
Range 25 - 50 18 - 55 43 - 55 35 - 55 46 - 60
Right nasal 46 ± 7*# 45 ± 8*# 51 ± 4 52 ± 5 55 ± 5
Range 25 - 55 21 - 55 42 - 57 45 - 65 44 - 63
Right inferior 58 ± 9*# 59 ± 12*# 66 ± 6 68 ± 3 70 ± 1
Range 33 - 75 21 - 75 50 - 70 60 - 70 66 - 72
Left temporal 68 ± 11*#§ 73 ± 15*#§ 87 ± 3 86 ± 6 88 ± 3
Range 43 - 88 35 - 90 80 - 90 70 - 90 76 - 90
Left superior 43 ± 7*§ 43 ± 8* 50 ± 4 46 ± 6* 53 ± 4
Range 25 - 55 20 - 60 44 - 58 35 - 55 46 - 60
Left nasal 48 ± 8*# 47 ± 9*# 52 ± 5 55 ± 5 59 ± 3
Range 25 - 65 22 - 60 42 - 59 45 - 60 53 - 63
Left inferior 57 ± 10*#§ 59 ± 11*# 66 ± 3 67 ± 4 71 ± 1
Range 30 - 73 26 - 70 60 - 71 60 - 70 67 - 73
One-way ANOVA with Scheffe´s post hoc test; * p < 0.05 vs. controls, # p < 0.05 vs. CBZ, § p <
0.05 vs. TGB
5.3.1.1 Risk factors for visual field defects
The etiology of epilepsy (symptomatic vs. cryptogenic) did not influence the prevalence of visual field
defects (chi square test, p = 0.06), nor the severity (mild vs. severe) of the visual field defect (chi
square test, p = 0.18). Furthermore, there was no difference in prevalences between patients treated
with monotherapy and those treated with add-on therapy (chi square test, p = 0.842). In the whole
group of 60 patients treated with VGB, the prevalence in males was 11/25 (44%, 95 % CI 24%-
64%) and in females 13/35 (37%, 95% CI 21%-53%). However, no statistical difference in the
prevalence between males and females was found with the chi square test (p = 0.118). In linear
regression, no significant correlation between the visual field extents and the duration of VGB
therapy or the daily or cumulative dose of VGB was found. Neither body weight, age of the patients
nor use of other GABAergic AEDs correlated with the visual field extents.
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5.3.1.2 Prognosis of visual field defects
The follow-up of 4 to 38 months (15 ± 7 months) did not reveal any significant reversion in the
constricted visual fields. Only one patient with mildly constricted visual fields in the first evaluation
had normal visual fields in the follow-up examination after cessation of VGB therapy. For the group,
the mean change in degrees in the cardinal meridians of the visual fields during the follow-up varied
from narrowing by only 1o to widening by only 2o. The age, duration of VGB therapy or cumulative
VGB dose did not influence the change in the cardinal visual field extents during the follow-up.
Twenty-nine patients had discontinued VGB therapy 2 to 28 months (10 ± 6 months) before the
follow-up examination; there was no significant difference in the change in visual fields between them
and those who continued on VGB. The correlation in the temporal visual field of the right and left
eye between the first and follow-up examination is presented in Figure 4.
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Figure 4. The change in the temporal visual field extents between the first (x-axis) and the
follow-up (y-axis) examinations. The spots over the diagonal line means better and below it
worse visual fields. (RE = right eye, LE = left eye).
5.3.2 Static perimetry (V)
Automated static perimetry revealed localised defects (one hemianoptic and two quadrantanoptic) in
three of the 15 TGB monotherapy patients. None of the TGB monotherapy patients had concentric
constriction in visual fields examined with static perimetry. The reliability criteria were within normal
limits in each eye. 
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5.4 Contrast sensitivity (III, V)
Contrast sensitivity was within age-dependent normal values (Mäntyjärvi and Laitinen, 2001) in all
patients with the exception of the patient in the TGB monotherapy group who had previously-
documented optic nerve atrophy and homonymous hemianopia, and of one patient (left eye) in the
VGB monotherapy group. For the group, no differences were found with the analysis of variance
(one-way ANOVA with Scheffe´s post hoc test) in contrast sensitivity between the patients treated
with VGB, TGB or CBZ monotherapy and normal controls (the right eye: F = 1.796, df = 3, p =
0.153, the left eye: F = 1.353, df = 3, p = 0.262) (Table 9). No difference was found between the
right and left eye in any therapy group. However, among the VGB monotherapy patients, positive
correlation was found with linear regression between the visual field extents and contrast sensitivity
values (for instance, the temporal meridian: the right eye R = 0.498, p = 0.005; the left eye R =
0.476, p = 0.006). In addition, if the results are considered according to the clinical categories of the
visual fields, a significant difference (p = 0.012 in the right eye and p = 0.045 in the left eye) was
revealed by the Kruskall-Wallis test in contrast sensitivity between the groups of patients with
normal, mildly abnormal and severely abnormal visual fields (Figure 5).
Table 9. Contrast sensitivity with Pelli-Robson letter chart in VGB monotherapy patients,
TGB monotherapy patients, CBZ monotherapy patients and in normal controls (mean ± SD).
VGB TGB CBZ Controls p
n = 30 RE, n = 14 n = 18 n = 35
n = 32 LE
Pelli-Robson
Right eye 1.76 ± 0.14 1.70 ± 0.14 1.78 ± 0.11 1.77 ± 0.14 0.153
Range 1.50 - 1.95 1.50 - 1.95 1.65 - 1.95 1.65 - 1.95
Left eye 1.74 ± 0.19 1.68 ± 0.12 1.78 ± 0.13 1.80 ± 0.12 0.262
Range 1.20 - 1.95 1.50 - 1.95 1.65 - 1.95 1.65 - 1.95
p with one-way ANOVA
Right eye Left eye
0
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1,5
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 Normal visual fields
(n= 17 RE, 19 LE)
 Mildly abnormal visual
 fields (n = 10)
 Severely abnormal visual
 fields (n = 3)
67
Figure 5. Contrast sensitivity in VGB monotherapy patients (mean ± SD).
5.5 Glare sensitivity (III)
The results of macular photostress and brightness acuity tests were within the normal ranges (Glaser
et al.1977) in both VGB monotherapy patients and CBZ monotherapy patients. None complained
about exceptional dazzling during the examination. The patients treated with TGB did not perform
glare sensistivity examinations.
5.6 Color vision (IV, V)
Abnormal color vision was found in 10 of 31 patients treated with VGB monotherapy (32%, 95% CI
16% - 48%), in 7 of 14 patients treated with TGB monotherapy (50%, 95% CI 24% - 76%), and in
5 of 18 patients treated with CBZ monotherapy (28 %, 95 % CI 7% - 49%) (Table 10). In the VGB
monotherapy group, all three patients with severely constricted visual fields, five of 10 patients with
mildly constricted visual fields and two of 19 patients with normal fields had color vision defects.
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Two patients in the TGB monotherapy group who had abnormal color vision, had quadrantanopias
on perimetry. 
Table 10. The frequencies of color vision defects in VGB, TGB and CBZ monotherapy patients
examined with the SPP2, FM100 and CVM712, (number of patients (%) with 95% (CI)). 
VGB TGB CBZ
(n = 31) (n = 14) (n = 18)
SPP2 3 (10%) 1 (7%) 0 (0%)
95% CI Upper 20% Upper 20%
FM100 9 (29%)  3 (21%) 3 (17%)
95% CI 13% - 45% Upper 40% Upper 34%
CVM 712 5 (16%) 7 (50%)  4 (22%)
95% CI 3% - 29% 24% - 76% 3% - 41%
SPP2 = Standard Pseudoisochromatic Plates part two, FM100 = Farnsworth-Munsell 100 Hue test,
CVM 712 = Color Vision Meter 712 anomaloscope
5.6.1 Standard Pseudoisochromatic Plates 2
Some patients in the VGB and TGB monotherapy groups had single red-green and blue errors in the
SPP2 plate test. Three patients in the VGB group and one in the TGB group missed the test. They
were not deemed to be congenital defectives because errors were not symmetric, as they are in
congenital color vision defects (Ichikawa et al., 1987). The patient with previously-documented optic
nerve atrophy in the TGB group did not see any of the plates, and did not perform other color vision
tests.
5.6.2 Farnsworth-Munsell 100 Hue test
There was a significant difference between the groups of  patients treated with VGB, TGB and CBZ
monotherapy and controls in the age-adjusted FM100 total error scores with ANOVA (F = 5.494, d
f = 3, p = 0.002 in the right eye, F = 5.231, df = 3, p = 0.002 in the left eye). Scheffe’s post hoc test
reveals the difference between the VGB monotherapy patients and normal controls. No difference
was found between the different therapy groups or between the TGB or CBZ groups and controls
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(Table 11). The errors accumulated in the third (green-blue) box in all patient groups. There was no
difference in the FM100 results between the right and left eyes in any group. A blue axis was found
in 4 (13%) of 31 VGB monotherapy patients, in 1 (6%) of 18 CBZ monotherapy patients, and in 2
(13%) of 14 TGB monotherapy patients. None had red-green axis.
Within the VGB group, with regard to the classification of visual fields, no difference (p =
0.059 in the right eye and p = 0.068 in the left eye) in the age-adjusted FM100 total error scores was
found by the Kruskall-Wallis test between the patients with normal, mildly abnormal and severely
abnormal visual fields (Figure 6).
Table 11. Age-adjusted FM100 total error scores (TES) of VGB monotherapy patients, TGB
monotherapy patients, CBZ monotherapy patients and controls (mean ± SD).
VGB TGB CBZ Controls p
n = 29 RE n = 13 RE n = 18 n = 47
n = 30 LE n = 14 LE
FM100 TES
Right eye 11.7 ± 4.5 10.9 ± 2.6 10.5 ± 2.3 8.9 ± 3.0 0.002*
Range 5.2 - 21.6 7.1 - 14.1 6.9 - 15.4 2.7 - 15.0
Left eye 12.0 ± 4.5 10.9 ± 2.9 10.3 ± 2.8 9.1 ± 2.7 0.002*
 Range 6.2 - 24.4 6.0 - 14.7 6.6 - 18.3 3.8 - 14.9
*One-way ANOVA with Scheffe’s posthoc test between the VGB monotherapy patients and normal
controls.
Right eye Left eye
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Figure 6. FM100 total error scores in VGB monotherapy patients (mean ± SD).
5.6.3 Color Vision Meter 712 anomaloscope
Abnormal red-green AQ was found in three of 31 (10%) VGB monotherapy patients, in four of 14
(29%) TGB monotherapy patients and in three of 18 (17%) CBZ monotherapy patients, whereas
abnormal blue AQ was found in two (6%) VGB patients and in one (7%) TGB patients, but not in
any CBZ patients. The red-green MR was abnormally wide in three (21%) TGB patients and in two
(11%) CBZ patients, but, surprisingly, was normal in all VGB patients. The blue MR was abnormal
in one (3%) VGB patient, in two (14%) TGB patients and in one (6%) CBZ patient. 
5.7 Dark adaptation (III)
Dark adaptation thresholds were measured in seven patients who had severely or mildly constricted
visual fields; six of them were being treated with VGB monotherapy, and one with VGB add-on
therapy. Only one monotherapy patient with severely constricted visual fields had slightly abnormal
thresholds in the right eye: 5.2 log units for cones,  2.9 log units for rods, and 2.8 log units for the
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rods in the left eye, but the time for both thresholds was normal. All others had normal dark
adaptation curves. 
5.8 Electroretinogram (I)
All the patients with severe visual field defects and 60% of those with mild visual field defects were
found to have reduced oscillatory potentials in ERGs. Patients with severe visual field defects also
had reduced amplitude of a and b waves in cone photoptic and rod scotoptic ERGs.
5.9 Neuroradiology (I)
All MRI of orbits, visual pathways, and occipital lobes were normal and did not reveal any new data
regarding the etiology of the visual field defects.
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6 DISCUSSION
6.1 Patients and controls
The unique patient population in this study provided a good opportunity to contribute to our
knowledge of  the effects of AEDs on visual function. Both GABAergic drugs examined, VGB and
TGB, are approved for the adjunctive therapy of partial epilepsy in adults. Consequently, patients
with initial or long-term monotherapy with these AEDs are difficult to find even world-wide. The
patients in the present study were on monotherapy, the majority on their initial monotherapy, with the
exception of VGB add-on patients in study II. On the other hand, the add-on patients made it
possible to compare the prevalence rates of VGB-associated visual field defects in patients treated
with monotherapy and add-on therapy. For studies I-IV, we identified patients with partial epilepsy
who, at the time of diagnosis, during 1988 to 1995, were randomly assigned to either VGB or CBZ
monotherapy in two clinical drug trials. They had already successfully used their initial monotherapy
for 2.4 to 10 years and still attended the outpatient Department of Neurology in Kuopio University
Hospital.
In the TGB study, the patient population was smaller and the patients were older than in the
VGB or CBZ groups, but this also is a unique patient population world-wide since all these patients
received TGB as long-term monotherapy for 1.9 to 4.6 years, after failure with their conventional
AED monotherapy. However, there are methodological problems in conversion studies. Ideally,
patients should  only have used single monotherapy earlier, to avoid the confounding influence of
different earlier treatments. Only two of the TGB monotherapy patients had received single AED
monotherapy earlier: the others had received various AED monotherapies, and two had received
VGB earlier. The duration of VGB therapy was short (3 and 9 months), and cumulative doses were
small in both cases. The subsequent TGB monotherapy had already continued for 32 and 53 months.
As it is difficult to find TGB monotherapy patients, we wanted neither to lose any of the patients nor
to start to select any of the patients. In this case, as the visual fields were normal we know that these
patients did not have VGB-associated visual field defects. We believe that the duration of TGB
monotherapy was long enough to allow us to identify the possible TGB-associated ophthalmological
adverse effects in our patients, although we cannot exclude the influence of earlier AED therapy on
visual function.
Generally, the normal values for different visual function tests are measured in healthy
controls, and accordingly, all controls in the present study were healthy volunteers. The best possible
control population would be similar epilepsy patients without any AED therapy, to permit the
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detection of the influence of seizures and epilepsy itself. However, epilepsy should  always be
effectively treated, as untreated epilepsy is a progressive phenomenon and repeated seizures may
cause neuronal loss and cognitive decline. It is considered unacceptable for ethical reasons to conduct
placebo-controlled studies if this involves leaving patients with active epilepsy untreated. Given the
situation we were in at the beginning of the study, facing a possibly serious drug-induced adverse
effect, it was not possible to collect a control group from among untreated epilepsy patients.
Consequently, we used normal values of different parameters which had been examined over many
years at our clinic in healthy volunteers, and which are used in both research and clinical work.
6.2 Ophthalmological findings
Visual acuities were normal in all patients regardless of the AED therapy used. Some patients had
ophthalmological diseases which caused decreased VAs, and the affected eyes were excluded from
the study. The results of the present study are in agreement with those of other studies which have
reported about normal or only slightly impaired VAs (Miller et al., 1999, Johnson et al., 2000). 
Surprisingly, the appearance of the retina was normal in all patients with VGB associated
visual field defects. In some studies, arterial narrowing, wrinkling retinopathy, abnormal pigmentation
and other nonspecific alterations have been described, but the association between these findings and
visual field defects is questionable (Krauss et al., 1998, Lawden et al., 1999, Miller et al., 1999, Wild
et al., 1999). In our study, some patients had retinal pigment epithelial scars from earlier central
serous chorioretinopathy episodes, but no retinal abnormalities possibly attributable to VGB therapy
were observed. In the present study, pallor of the optic nerve heads was observed only in the most
severe cases; this finding is in line with those in other studies (Lawden et al., 1999, Wild et al., 1999).
This mild optic nerve atrophy might be a consequence of ganglion cell loss, possibly secondary to cell
damage in  inner retinal layers. In case reports, the optic nerves and tracts of  patients with VGB-
associated visual field loss showed severe atrophy mainly in the peripheral retinal fibers with relative
preservation of macular fibers (Buncic et al., 2001, Ravindran et al., 2001).
74
6.3 Visual fields
6.3.1 General aspects
The main result of the present study was that 40% of the epilepsy patients treated with VGB
monotherapy or add-on therapy were found to have asymptomatic bilateral concentric visual field
defects, whereas none of the TGB or CBZ monotherapy patients had similar constrictions. Three
patients in the TGB group had localized defects from earlier brain lesions. The prevalence of VGB-
associated visual field defects in the present study is in accordance with that reported in other studies.
However, the prevalence rates in different studies range from 13 % to over 80%, the mean being
39% (95% CI 36% - 41%). This variation in prevalence rates might be partly explained by methods,
i.e. automated static or manual kinetic perimetry, and the limits of normality used. There are no
accepted criteria for concentric visual field defects, and changing the limit of normality does alter the
prevalence rates significantly. In addition, study populations also differ from each other which can
influence the rate of successful and reliable perimetry outcomes. There are probably both
underestimations as well as overestimations in the previously reported prevalence rates. In several
studies concerning VGB-associated visual field defects, the patients suffered from drug-resistant
epilepsy and received AED polytherapy which can influence the outcome of visual field examination
and other psychophysical tests because of fatigue and psychomotoric slowing. We believe that with
our patient setting we were able to avoid any possible additive toxic effects of AED polytherapy.
Moreover, the patients  good seizure control for years eliminates the detrimental effect of epilepsy´
itself on visual perception.
In the present study, the visual field defects in patients treated with VGB was severe in 13%
and mild in 27% of patients. In a cohort reported by Wild et al. (1999), the corresponding rates were
severe in 15%, moderate in 10% and mild in 3%, according to their categories. The patients in the
present study were asymptomatic: only two patients had bumped into objects. This does not differ
from findings reported in other studies (Daneshvar et al., 1999, Wild et al., 1999, Hardus et al.,
2000a). Generally, concentric visual field defects, for instance in patients with retinitis pigmentosa,
affects the performance of daily tasks only minimally (Szlyk et al., 2001). In the symptomatic cases
reported so far, only in a minority of patients has the defect been so severe that it has restricted their
daily living (Eke et al., 1997, Krauss et al., 1998, Wilton et al., 1999, Manuchehri et al., 2000).
According to the criteria of the Finnish Ministry of Social Affairs and Health for visual handicap
(Sosiaali- ja terveysministeriön päätös n:o 1012, 1986), a majority of the patients, who had severe
visual field defect were mildly (<50%) visually handicapped.
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The extents of visual fields were significantly constricted in the VGB group as compared with
those in TGB group, CBZ group or normal controls. Some authors have emphasized that VGB-
associated visual field defects are predominantly nasal and concentric only in severe cases (Lawden
et al., 1999, Wild et al., 1999, Midelfart et al., 2000), whereas other studies have shown that
temporal fields outside of the limits of automated perimetry are also regularly affected (Miller et al.,
1999, Hardus et al., 2000a,b). We found a significant difference in all meridians of visual fields
between VGB patients and normal controls or CBZ patients which supports the idea that defects
develop in the entire periphery of the visual field leading to concentric constriction of the visual fields.
Because the hill of vision is physiologically asymmetric, this type of constriction will therefore reach
the nasal border of the central 30  of static perimetry earlier than its temporal counterpart. In theo    
follow-up of visual fields in patients treated with VGB, the temporal extent of the visual field must be
examined to at least 70 . If minimal visual field changes in the periphery are ignored, a falseo
impression of normal field may result (Midelfart et al., 2000, Schiefer et al., 2000 Hardus et al.,
2001a). Pre-existent visual field defects associated with epilepsy or with background brain pathology
may cause false positive findings, but the worsening of a pre-existing defect might also be
overlooked. Certain individuals need several training perimetries before producing reliable fields on
automated static perimetry. Peripheral depressions and an unaffected central field are typical findings
in an inexperienced testee (Wild et al., 1991, Olsson et al., 1997).
6.3.2 Methodology
The ideal visual field test would be easy to perform and 100% reliable, but unfortunately, we have no
such test. In recent years, we have learned to rely almost completely on automated tests in clinical
routines. In the present study, kinetic perimetry with the Goldmann perimetry was chosen to test the
full limit of peripheral vision, as earlier reports had described concentrically constricted fields in
patients taking VGB (Eke et al., 1997). When the present study was begun, we had no knowledge
about the capability of automated perimetry of 30o to detect incipient concentric constriction in the
peripheral visual field. To minimize variability on the part of the examiners, the same ophthalmologist
(the author) calibrated the Goldmann perimeter and investigated all the patients during the study. To
confirm our first results, repeated visual field examinations were performed within a few months in
all VGB and CBZ monotherapy patients, and some of the VGB patients underwent an additional
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neuro-ophthalmological examination including kinetic perimetry at Turku University Hospital. An
independent neuro-ophthalmologist (Professor Eeva Nikoskelainen) verified the findings.
We believe that the possibility of conversion-reaction or malingering as a cause for visual field
defects is excluded in the present study. Unlike malingering patients, none of the patients with visual
field defects had clinical symptoms, or demands for financial compensation at the time when the
visual field loss was detected. The appearance of kinetic visual fields was not typical for conversion
(Trauzettel-Klosinski, 1997); visual fields were not spiraling, constriction was visible in all examined
isopters, and there were no crossing isopters. During the examination, the size of the isopters was
randomly checked again, and after the kinetic perimetry, the visual field constriction was verified with
careful confrontation at different distances. 
The Goldmann perimetry has been found to be a reliable method in patients with neurologic
diseases (Li et al., 1978, Beck et al., 1985, Manji and Plant, 2000).The benefit of testing visual fields
with the Goldmann perimeter is that the operator can give guidance and encouragement to the subject
and tailor the test to the cognitive and attention level of the subject. In automated perimetry, the
testing procedure is conducted by the computer with a limited influence by the operator, and this has
been shown to be too demanding and fatiguing for some patients, causing false abnormal results. In
addition, it is conceivable that 30o static perimetry alone may not detect all VGB-associated visual
field defects (Wild et al., 1999, Schiefer et al., 2000). Newly designed short perimetric programs (for
instance, the Swedish Interactive Testing Algorithm (SITA) by Humphrey) may be performed
successfully and may be more reliable even in children and patients with learning difficulties (Morales
et al., 2001).
6.3.3 Risk factors for visual field defects
Linear regression analysis did not reveal any correlation between visual field extents and duration of
VGB therapy, VGB dosage, or cumulative dose of VGB consumed during the treatment. The
evaluations of the cohorts by Marketing Authorization Holders (CPMP report /1357/99) and Wild et
al. (1999) have, however, found an increase in the cumulative incidence within the first 2 kg of VGB
intake and within 3 to 4 years of treatment. In studies where a positive correlation was found
between the duration of VGB therapy and visual field defects, or between the cumulative dose of
VGB and visual field defects, the mean duration of VGB therapy was 3 years (Hardus et al., 2001a)
and 6 years (Manuchehri et al., 2000), and the cumulative dose <2kg (Hardus et al., 2001a) and 3.6
kg (Manuchehri et al., 2000). The probable explanation for our result is that majority of our patients
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had received VGB for so long that the cumulative doses of VGB were so high that it was impossible
to detect the threshold effect.
In the present study, males had a slightly increased prevalence for visual field defects (44% in
males vs. 37% in females), but the difference does not reach statistical significance. As earlier studies
have shown that male gender carries an approximately two-fold increased risk for VGB associated
visual field defect (Arndt et al., 1999a, Wild et al., 1999, Hardus et al., 2000a, Manuchehri et al.,
2000, Hardus et al., 2001a), the retinal toxicity of VGB presented as an all or none response might
be genetically based affecting males more frequently than females.
It has been suggested that combination therapy with other AEDs and VGB is more toxic to
retina than monotherapy (Harding, 1997, Arndt et al., 1999a) but this suggestion has been criticized
(Hirsch, 2000). Other GABAergic drugs in particular have been suspected but no studies have been
published to confirm this hypothesis. We did not find more visual field defects in epilepsy patients
treated with polytherapy than with monotherapy. Neither did we find differences in visual field
extents between those patients who used other GABAergic AEDs, gabapentin or topiramate in
addition to VGB and those who used other AEDs. However, in view of the small number of patients
involved, we cannot exclude their influence. Visual field constriction during treatment with another
GABAergic AED, progabide, has only been described in one patient (Baulac et al., 1998). Recently,
Lindberger et al. (2000) did not find visual field defects in epilepsy patients with gabapentin therapy
in a study of gabapentin versus VGB as first add-on, in which standardized perimetry examination
was offered all patients at the end of the study.
6.3.4 Prognosis of visual field defects
Study II showed that VGB-associated concentric visual field defects are not reversible. This finding
is consistent with that of other groups (Hardus et al.2000b, Johnson et al., 2000 and Paul et al.,
2001). Anecdotal reports of reversed visual field defects have been presented (Versino et al., 1999,
Giordano et al., 2000, Krämer et al., 2000) but no significant improvement in visual fields has been
published in larger series. Improvement in visual fields in repeated examinations must be interpreted
with caution due to the learning effect (Wild et al., 1991, Vanhatalo et al., 2001). In the present
study, only one patient showed clear improvement from mildly constricted fields in the first
examination to normals in the follow-up. It was not possible to identify progressive deterioration in
the visual field constriction with continued therapy, and there was no evidence to suggest a recovery
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when VGB was discontinued. This supports the case reports and studies published so far (Hardus et
al., 2000b, Johnson et al., 2000, Malmgren et al., 2001, Paul et al., 2001). Neither the age of the
patients, the duration of VGB therapy nor the cumulative dose of VGB correlated with the change in
visual field extents during the follow-up. At present, the data suggest that VGB-associated visual
field defects are at least long-standing if not permanent.
6.4 Contrast sensitivity
The results of contrast sensitivity examinations were within normal ranges in most patients regardless
of the AED therapy received when compared with our age-dependent normal values. However, a
correlation between contrast sensitivity and visual field extents in patients treated with VGB was
found. The patients with constricted visual fields had significantly lower contrast sensitivity values,
which probably indicates retinal toxicity of VGB. It has been hypothesized that GABA is involved in
the center-surround antagonism at the level of amacrine and horizontal cells (Falk, 1991, Harris et al.,
1995) which is an important function in contrast sensitivity. In the study by Sartucci et al. (1997),
add-on  therapy with VGB had beneficial effect on the contrast sensitivity in patients with refractory
epilepsy. Their study showed a constant and progressive recovery of contrast sensitivity after adding
VGB on CBZ monotherapy, the most prominent changes being in the intermediate frequencies.
Better seizure control with a more efficient treatment regimen as well as the learning effect might
explain their results.
The weakness in the methodology of the present study is that only one spatial frequency
(3cpd) was tested. However, intermediate spatial frequencies from 3 to 5 cpd are the peak contrast
sensitivity and have been suggested to be the most important feature of contrast sensitivity function
in everyday tasks such as reading. In two studies regarding the effect of GABAergic drugs,
midazolam and lorazepam, on contrast sensitivity function in healthy volunteers, the most prominent
impairment after administration of these drugs was in the low to intermediate spatial frequencies (Blin
et al., 1993, Harris et al., 1995). The method used in this study, the Pelli-Robson letter chart, has
been found to be reliable in detection of intermediate spatial frequency sensitivity loss (Rubin et al.,
1988). Thus, it can sufficiently reveal the changes in the contrast sensitivity caused by the AEDs
evaluated in the present study. In a recent study regarding performance in daily tasks of patients with
retinitis pigmentosa, Szlyk et al. (2001) found that patients whose Pelli-Robson contrast sensitivity
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was greater than 1.4 had mild or no difficulties in reading, mobility and peripheral detection. Most of
the patients in the present study exceeded this limit.
6.5 Glare sensitivity
In contrast to studies by Bayer (1991) and Bayer et al. (1995a,b), we found no enhanced glare
sensitivity in VGB nor in CBZ patients. We measured glare sensitivity in photopic conditions and
with high contrast, while Bayer used a Rodenstock Nyktometer with mesopic light and low contrast,
which is probably more sensitive to minimal changes in glare sensitivity. The normal results of
macular photostress tests support the findings of other investigators that VGB´s retintoxic influence
is directed more to peripheral than to central retina. Macular photostress and brightness acuity tests
were not carried out in study V, so the possible effect of TGB on glare sensitivity remains unclear. 
6.6 Color vision
In the present study, acquired red, green and blue color vision defects was associated with AED
therapy regardless of the drug used. The defects resembled tritan-like Verriest type III mixed blue
and red-green defect (Hart, 1987) in the majority of the patients, but there were also both
predominantly tritan and deutan defects. An abnormally high total error score was found in 9 of 31
(29%) VGB monotherapy patients. Bayer (1991) reported a prevalence rate as high as 65% in VGB
add-on patients using the same normal values of Verriest et al. (1982) as we did. However, the
superimposed effect of polytherapy in his patients cannot be excluded. The results in recently
published papers concerning VGB-associated visual field defects and color vision are not comparable
with ours because of the different method used. In the present study, patients treated with VGB had
color vision defects in association with the visual field defects, which supports the idea of
retinotoxicity as a cause of the visual field defects.
The present study is the first one regarding the effects of TGB on color vision, and it seems
that TGB can also cause color vision defects in a large number of cases. However, earlier AED
monotherapy can affect color vision as well, although the patients concerned had received TGB
already for 2 to 4.5 years as monotherapy. Normal aging changes, such as subtle lens opacities, may
be confounding factors; the TGB monotherapy patients in the present study were older than those in
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the VGB and CBZ groups. However, on the basis of the effects of nicopetic acid in GABAergic
transmission in the animal retina (Perlman and Normann, 1990), it is possible that TGB might
interfere with color perception. Future evaluation of color vision in epilepsy patients treated with
initial TGB monotherapy will give us more information about the issue.
In CBZ patients, we found color vision defects in 3 of 18 (17%) with the FM100 Hue test.
Recently, Lopez et al. (1999) found abnormal color vision with binocularly performed FM100 in
67% of epilepsy patients treated with CBZ monotherapy. Our results are in line with the findings of
other investigators (Paulus et al., 1996, Bayer, 1991, Bayer et al., 1991a,b, Bayer et al., 1997) who
have reported elevated FM100 total error scores and accumulation of errors along blue axis in CBZ
monotherapy patients.
The methods we used in color vision measurements were conventional, commercially
available tests, and the conditions were standardized with respect to illumination. All examined eyes
had good visual acuity and none of  the patients were taking medications affecting color vision other
than AEDs. FM100 seems to reveal most reliably color vision defects, while SPP2 and CVM 712
anomaloscope, although the tests with them are short and easy to perform, do not seem to be
valuable in screening possible retinotoxicity of AEDs.
6.7 Dark adaptation 
It was rather surprising that dark adaptation curves were normal in patients with VGB associated
visual field defects. This finding is consistent with those of other investigators who have also found
normal dark adaptation thresholds in patients with severely constricted visual fields (Bayer 1991,
Ruether et al., 1998, Besch et al., 2000). The method used in the present study, the Goldmann-
Weekers adaptometer records rod thresholds in the paracentral area (at a distance of 18o from the
fovea centralis). It is possible that the retinal network in that part of the retina is not damaged by
VGB to the extent which is observable in the conventional dark adaptation examination.
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6.8 Electroretinogram
The ERG is a sensitive and objective tool for detecting toxic effects on the retina. In the present
study, electrophysiologic results were available only in a minority of patients treated with VGB and
not at all in patients on TGB or CBZ. All patients with VGB-associated visual field defects who
underwent ERG examination had similar changes to those reported in other studies (Arndt et al.,
1999a, Krauss et al., 1998, Harding et al., 2000b). In the context of VGB-associated retinal toxicity,
the confounding effect of increased retinal GABA levels on ERG even in  patients without visual field
defects might diminish its worth in diagnosis and follow-up of patients on VGB therapy (Duckett et
al., 1998, Brigell, 1998, Harding et al., 2000a, Hardus et al., 2001b). On the other hand,
electrophysiological markers have been suggested to indicate the mechanism responsible for the
visual field defects, and might be used before the field loss becomes established. According to results
in ERG and EOG, the site of retinal dysfunction has been identified in the amacrine and Müller cells
in the inner retina (Harding et al., 2000b, Coupland et al., 2001, Hardus et al., 2001b), in the cones
(Krauss et al., 1998, Miller et al., 1999, Ponjavic and Andréasson, 2001), and in the outer retinal
layers (Arndt et al., 1999a) but the exact mechanism of the dysfunction has not been elucidated with
electrophysiological examinations.
6.9 Possible explanations for VGB-associated visual dysfunction
Since the first detection of VGB-attributed visual field constriction, many speculations about the
mechanism of the phenomenon have been presented, but no convincing mechanism for VGB’s retinal
toxicity has been published in studies conducted to date.
Epilepsy itself and the detrimental effects of AED polytherapy have been suggested to play a
causative role in the occurrence of visual field defects (Wilson and Brodie, 1997, Harding, 1997). It
was assumed that the outcome in visual field testing might have been influenced by fatigue and
psychomotoric slowing caused by the high frequency of seizures, underlying severe brain pathologies,
and AED polytherapy in patients with drug-resistant epilepsy (Backström et al., 1997, Harding, 1997,
Arndt et al., 1999a). VGB has not been found to cause deterioration in cognitive function, attention
or concentration evaluated by neuropsychological tests (Saletu et al., 1986, Dodrill et al., 1993,
Ylinen et al., 1995). On the contrary, patients with clinically successful VGB monotherapy performed
better on retrieval from delayed verbal memory, flexibility of mental processing, and psychomotor
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speed when compared with patients receiving CBZ (Kälviäinen et al., 1995). In the present study, the
patients who had visual field defects were seizure-free and had normal general intelligence and
concentration ability verified by formal neuropsychological testings. Thus, detrimental cognitive
effects of epilepsy itself or AED therapy do not seem to be the probable explanation for VGB-
associated visual dysfunction.
Visual dysfunction with the use of VGB has been attributed to elevated levels of retinal
GABA which has been suspected to be toxic to GABAergic cells in the retina (Krauss et al., 1998,
Harding et al., 2000a, Coupland et al., 2001). Highly elevated levels of retinal GABA after
administration of VGB have been shown in several animal studies (Neal et al.,1989 and 1990, Cubells
et al., 1987, Sills et al., 2001), but the toxic effects of extra GABA in the retina are not known.
Generally, released GABA is rapidly removed by uptake mechanisms and metabolized in glial cells or
presynaptic neurons. The effects of elevated retinal GABA on ERG have been shown in several
studies (Kupenova et al., 1991, Arnarsson and Eysteinsson, 1997), but whether this is the same as the
mechanism which causes the visual field defects is not known (Duckett et al., 1998, Harding et al.,
1999, 2000a,b, Brigell et al., 2000). If this hypothesis is correct, then other compounds that affect
CNS GABA levels could potentially cause similar visual disturbances in susceptible patients (Beran
et al., 1998, 1999). However, Sills et al. (2001) have shown that TGB does not elevate retinal GABA
in a similar manner to VGB. On the basis of the results of the present study, the GABAergic
mechanism of action per se is not critical in the development of visual field defects.
Accumulation of VGB molecules in the rat retina have been shown by Sills et al. (2001). The
dose-related VGB concentrations were significantly higher (300%-800%) in the retina than in brain
tissues. Moreover, active transport and accumulation of immunolabelled VGB in the amacrine and
Müller cells have also been found in animals (Pow et al., 1996, Crook and Pow, 1997).  In humans,
histopathological examination of the retina of an epilepsy patient with VGB-associated visual field
defects suggested that the primary site of injury lies within the ganglion cells, although both INL and
ONL presented loss of nuclei (Ravindran et al., 2001). This VGB accumulation hypothesis needs
more data in different species, and also additional examinations of available human specimens. 
Hosking et al. (2001) showed that ocular blood flow is reduced in epilepsy patients treated
with VGB when compared with epilepsy patients treated with conventional AEDs or normal controls.
They suggested that this reduced ocular perfusion may have implications in the impairment of visual
functions associated with VGB. This hypothesis is based on the finding that epilepsy patients treated
with VGB have also exhibited reduced cerebral blood flow (Spanaki et al., 1999).
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6.10 Implications for clinical practice
Epilepsy is a disease which can be lethal in patients with uncontrolled seizures, and requires long-
term, even life-long therapy. The goals of AED therapy are to control seizures and to improve the
patient’s quality of life without subjecting the patient to untoward effects of the therapy. All AEDs
pose some risk for ophthalmological problems, as does uncontrolled epilepsy itself.
VGB is currently marketed in over 65 countries world-wide. In the USA, VGB has not had
marketing authorization and after the risk of visual field defects was discovered the manufacturer of
VGB received an “unapprovable” letter for VGB in 1998 from the Food and Drug Administration.
In 1999, the Committee for Proprietary Medicinal Products of the European Agency for Evaluation
of Medicinal Products (EMEA) in their opinion regarding the risk related to visual field defects,
recommended the maintenance of the marketing authorizations for VGB only under specific
conditions in the European Union (CPMP-report/1357/99). VGB should currently be used only in
combination with other AEDs for patients with resistant partial epilepsy in situations where all other
appropriate drug combinations have proved inadequate or have not been tolerated. Currently, the
benefits of treating infantile spasms with VGB monotherapy  seem to outweigh the risks, but further
prospective studies and follow-up of  children are needed to evaluate the place of VGB in this
indication (Vigabatrin Advisory Group, 2000).
If VGB is used, visual field examination should be performed before the start of treatment and
at regular intervals during treatment. The relationship between the duration of exposure to VGB and
the development of the field defect is largely unknown; six-month intervals have been suggested for
the follow-up, but there is no current clinical evidence to support this or any other interval. More
data are needed to determine the clinical course of VGB-associated visual field defects in order to
determine the proper follow-up interval. Confrontation testing does not reliably identify the defect.
The visual change does not typically involve the central visual field and therefore remains
asymptomatic in a majority of cases.
Visual field examination should be performed under standardized, repeatable and comparable
conditions using a Goldmann kinetic perimeter, or a Humphrey or corresponding static perimeter.
The temporal extent must be examined to at least 70o. Any new visual field defect that is not
previously documented should be subject to a repeat assessment. VGB-attributed visual field defects
might be overlooked in patients with visual field defects from other causes. Patients with pre-existent
visual field defects due to other causes should not be treated with VGB. Reliable assessment of visual
fields in children over 9 years of developmental age is possible with perimeter, especially with a
84
Goldmann kinetic perimeter. Reliable assessment of visual fields in children less than 9 years of
developmental age is seldom possible. Other methods, such as ERGs and field-specific VEPs, have
not yet been validated in the diagnosis or exclusion of VGB attributed visual field defects.
Methodological limitations in the follow-up must be taken into account when evaluating the risk-
benefit profile of VGB as add-on treatment in partial epilepsy in young children. 
The risk of visual dysfunction must be balanced with the improvement in quality of life in
patients whose seizures are controlled by VGB. Severely constricted visual fields limit the ability of
the patients to perform activities of daily living, especially motility, but most of the patients with
VGB-associated visual field defects are unaware that they have any visual deficits. One specific risk
in epilepsy patients who are seizure-free concerns the implications of a visual field defect for driving
(Manji and Plant, 2000). The visual field requirement for a driving licence in the EU demands a field
(corresponding Goldmann III/4 spot size) extending at least 120o horizontally and 20o from the
central fixation point above and below.
Patients who currently are well-controlled with VGB and have been treated for years with the
drug without developing the visual field defect should be informed of the risk. They should also be
told about the limited data which currently suggest that the defect is unlikely to develop if perimetry
gives normal results after more than three years of treatment. Therefore, it seems to be acceptable to
continue VGB in a majority of the patients, as long as there is adequate follow-up. In our series, the
outcome of patients after discontinuation of VGB was good, with only one patient with normal fields
having to be put back on VGB due to difficult seizure relapse and adverse effects with other AEDs.
One patient with a severe visual field defect needed polytherapy before she became seizure-free again,
although she had been totally seizure-free with VGB monotherapy for several years. Other
monotherapy patients were successfully treated with other AED monotherapies, and in a few cases
treatments could be totally stopped. Most of the add-on patients retained good seizure control with
other treatment options, and moreover, some patients with originally refractory epilepsy became well-
controlled after VGB was switched to other add-on AEDs.
VGB has been widely used in the treatment of infantile spasms and many specialists regard it as
the drug of choice especially for infants with definite or possible tuberous sclerosis (Appleton, 1998,
Osborne et al., 1999, Vigabatrin Advisory Group, 2000, 2001). Limited data also suggest that VGB
could be withdrawn without relapse in infants who have been spasm-free for six months. However,
it has been suggested that VGB should not be used as the first choice in the treatment of infantile
spasms (Gross-Selbeck, 2000, Riikonen, 2000, Prasad et al., 2001, Lux et al., 2001). Follow-up of
children treated with VGB as infants is needed to evaluate the place of VGB in this case. Currently,
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VGB remains the drug of choice for short-term treatment of  infantile spasms. 
6.11 Future studies
The present study contributes to our knowledge of the retinal toxicity of AEDs. Our results  confirm
the causative role of VGB in the development of concentric visual field defects in association with
impaired visual function in some users. Longer follow-up studies are needed to discover the long-
term outcome of VGB-associated visual field defects after cessation of therapy, and the evolution of
visual function during continued therapy. However, the most important challenge in the future is to
elucidate the pathophysiological mechanism(s) behind VGB-associated visual field defects. The
elucidation of the exact mechanism of VGB’s retinal toxicity may enlarge our knowledge and
understanding about the function of the complex neuronal network of the human retina.
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7 CONCLUSIONS
1. Only patients treated with VGB monotherapy have bilateral concentric visual field defects. The
extents of the visual fields were significantly constricted in patients treated with VGB
monotherapy as compared with the visual field extents in CBZ monotherapy patients or healthy
controls. Treatment with VGB causes asymptomatic bilateral concentric visual field defects. (I)
a) The overall prevalence of concentric visual field defects is 40% in both VGB
monotherapy patients and in add-on patients. The constriction is severe in 13% and mild
in 27%. (I, II)
b) The visual field defects are neither reversible after cessation of the drug nor progressive
with continued treatment. Some patients may have improvement in their visual fields
after stopping the drug. (II)
c) The daily or cumulative dose of VGB, duration of treatment, age, gender or body weight
of  the patients, or administration of other GABAergic AEDs do not correlate with the
visual field constriction. According to the literature, however, male gender, cumulative
dose of 2 kg of VGB and duration of treatment for 3 years have been shown to be risk
factors. (I, II)
d) Color vision and contrast sensitivity are significantly impaired in patients who have VGB
associated visual field defects, which supports the idea of the retinal toxicity of VGB.
VGB does not affect glare sensitivity. (III, IV)
2. Another GABAergic AED, TGB, does not cause concentric visual field defects in the same
way as VGB. Visual field defects associated with the use VGB are not a class effect of
GABAergic AEDs. (V) 
3. Treatment with both TGB and CBZ causes acquired color vision defects in some patients.
Contrast sensitivity is not affected by TGB and CBZ. (III-V)
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